var title_f7_47_7920="Pyoderma gangrenosum cribriform";
var content_f7_47_7920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 282px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple active and healing lesions of pyoderma gangrenosum with cribriform scarring in patient with inflammatory bowel disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Samuel Moschella, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7920=[""].join("\n");
var outline_f7_47_7920=null;
var title_f7_47_7921="Fenoverine: International drug information";
var content_f7_47_7921=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fenoverine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fexadin (KR);",
"     </li>",
"     <li>",
"      Spasmopriv (CN, CO, IN, MX, SG, TH, TW);",
"     </li>",
"     <li>",
"      Tavidan (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3335265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Gastrointestinal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F3335266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of gastrointestinal spasm, gastric and duodenal ulcer, monorrhagia, biliary duct and urinary tract spasm",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F3335268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: 100 mg 3 times/day or 200 mg twice daily with meals for up to 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elderly: Adult dose of 300-400 mg/day should not be exceeded",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3335269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 100 mg, 200 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10490 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7921=[""].join("\n");
var outline_f7_47_7921=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302643\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335265\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335266\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335268\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821168\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335269\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10490\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10490|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_47_7922="MRI synovial chondromatosis";
var content_f7_47_7922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Synovial chondromatosis of the hip on magnetic resonance imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 449px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHBAfADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyQkgZwMfSlADdlP4ULscnn8KIrNpHzFJigBDtA4Az9KoXMgklClQCDxgVpXCNEp3VnwhXm5FAChFOMgbvpV6AqUwNuR7VC20SYA4odPJBbHBoAt8Feg/Ks+YZO7Ax9K0IsSQe9RPblouKAIUwU5A/KmOMNwB+VTeUUUbqjdMtmgBu8jsPyq0nKc459qqSICMinQsSMUAaVpjcAQv5Vdb5eRt/KsSCciUhugqys7bjk8dqANSG5LELhfyFGpShUHAJ+lY8Tt9rVgeM1pX8qSRKG4OKAIUt/wB35jKuPpURb5uVXH0p4mM0Yj3YpkxC/KOcUADMAMhR+VISCmcL+VPijyuT3qtJkS4HQGgC1GF8ptwGfpVePiTOFI+lSyNsi+tRqPlzQBOpDtyo49qfMVxwB+VPhVVTc1Q3KhwdpxQA+BFPzEDP0q0km9vLwuOo4FV7HhcNSzZhZpQeMUAUNUlHmMFAyOBxXV+DCmm6b5+xfNf1Ari4y1zdJEOrtmup1W7Sysooo/vgYNAHbxyC409p7gISenyiuFuCi3MrrjGeBgV0miM91pGHJ5XiuO1cPbzsF55oAmMwYnIXH0FVkXM2SFx9Ky5JpUPfmnCeUR7hQBrTXG0hVC4+gqSLEoyFH5VzjXUhfLVZgvpf4OlAHTIURduAD9BVzTIhJOFdVIPqBXJNfybwW6VpWuqsu106rQBoeJfDko/fRoNvXgVzpQwOgIAI9q9M07Vk1DTDFKBuxXnficiG5dV9eKAO20WUT6XtZVPHoKojNvO3ClO+QKPA1wstiQxyRVbWJjFcOO1AFXUUimcsiqPwFZU6hTgBfyq8D5hzmqd3gPxQA3AMf3R+VQjAboPyqZGytRSD5uKAJGYccDP0qyke9OAM/SqqqDj1qe2m2SAP0oAmCrEMlACPasm9PnyZCgEe1bl2VkiJXFZCqNxzQBEhyu1wCR7UfKWwQMfSgqySU2UEc0AW2RTDhVX8qrRjacYH5VJbOeM0+VOSRQBC5HXaPyqPAIzgflUjDIqIg7aAFjwWzgY+lSyH5cKo/KmRp3pXfaaAAKhTkDP0qJECyAHH5VfitI7uL92+GpGs/sa4kO5vWgCJo/McIAMfSrAt4412kKT9KrJcshbIGT0qBmkZtzsRQBPIY48ldoP0phkM6ZYg49qqzDJz6VNZkbDnmgBVAEnTirC7gf3ZquGyKliLZz2oAgvrzJWNhlqSBQGyRgGoXT/SWPWnjfnB6CgCd41IIUnJqRUb7KVkGR61GlwsZAIzV6Ke3ddjZXNAFC2kBDJuwKnww4BqjNthuvl+4avQjfhgcUAEhOw7uvrVeLIzk9at3IAQAfiarqoUgkUAOIGKiUBW6dasSMMDbxUZBIzQA5bff8w6nmmsuw4IIqaIlcHNPmkXyySKAKMHNwoB71LrLMCAvTFOgC43Y57VDcSGVtpGaAGwMwQMv41cWRWA55qGBNqGiNcPx0oAuF8IKsWdsrfO1VUXf34FaVq6pHz2oAqahGEwc8elUQe9Wb6TzJOPu1AMMwAFAFhZDsANRklnx2omyuBUkC5xnmgC1BHkjbVfXJFSIQr949a19PtysbSMPlArk9Tn869kcfdXpQBZ0GHz9T+XnbT/ABBI41AR4Oc1o/Duza5vJpQMgDNO1Gxe58QHj5VbmgDuNFEcOhoTw5WuH1pS187HpmuinvvJVIIxwoxWPqkRlG9OT3FAHPXBVpAMVK6AQ5olgIfPIqGeSTG0jgUAVWZNx45qaHDfdGKiAxyBzUwJCZA7UAKYwWPepbXCyYxSacHkc7hxWhDa+ZdqFoA1dEZ0bC8CsTxfGwmD4rTuL0adIsY607WITd2ayYzkUAVvBLmNDt4FS62we5IB5qPRALKFtw4rOuboS6mVB60AJYzMLrymqzqK+XIPQ1nzsba/RyOuK1NVG+JHHXrmgCmnFPnX5QRUafdBzUz/ADxe1AEEXJp8+CnHUUyP5Tihu+TQA9bj93tzzQIiVLZqk3+s68VeEm2IDPFAEDAspJPNQYOMNUzHAxUbDjmgB0LbW9qlnfA4qAZA4HFPlGY85oAI2LKajkOFp9r0IP4UjLl+RQA+BeOaGRcnNPiYIPmqrLISx64oAmiTyn3xsQK0zcLeQeWR84FUrWSPbtfFCN9mlLAHYaAGPZkMSTyKrtkPg9atE3E8hkiU7PWo5xk5P3+9AFaRQahtm8u4welSnO7npUUy7WV6ALSAbX9ajeRo48Z60rElcLxzzVd23XKp1xQBN/yyBxzUtqglYhmxUDPyQeBSqxiBPagC22mLncZMelTafZxTXIikcAZ+9Wf57cAknPY1YtXLz+UiHLcEjtQAut26Q3YRMMo7iorWT+Hqan1azezl2li5YZ57VQT924cHNAGvKoMQwKgCZ61YgYPEDn5jTJVI7c0AVZQQcjoKlQDbntUQYs2PwqfIUBSKAFUce1Q3RBXA4qbncAOlVrhcyjmgCWI4ixj8aqoczGppGKrtA4qK3GWLHpQBOcrx1zSDqMdafJyw4pCCcDoaAHhio+lSGYleOh61A8h4TGalC7EHH1oASTBTg802Ac59Ka5DHCmpolwuaAFf5/8AGrNhGzSBRVQEs+Peuh0S0y/mN0FAFnXJFsdFCg/Owrz+SNmjwPvu1dd4sn8wgfwKKyfCWnPq+rpgHykOfagDvPB2n/2VoDSuuJZF9OtIlp5MMlzMMu3IrZ1eVYY44RgKgxiucvNRe6PlLwgoApIQGaRzkmoxMoLFqZcOqgxkjFVrdomclzwKAJ5RBOMkYP0qjcabIQTENy1q27pcv5aRYX+9iprmCe1OYm3L1xQBztvp8jN8yEEdqs/2c2BlcfhWvDcGVgCmGqO+vfJwuBmgCKy01I8mTC0sSL9tCwcnOM+lMa4adVTBBbsK2dK0Wa1h+0yqQDyM0AYOvWeydS3zNVqN/wDQlRvSp9XKyEvVIBnh5GAKAIJlxCwrFsLV31MN1FdDaW/2iXZmtKx0hbW5DOeD3oA4/wASJsdMdquWTi5stjdQKd44tjFKGH3T0rP8PTgtsPegCQLskKelTFsKARin3seLsbe9LMuxRu70AVZOOaj+8OtPmJPFRoD0FAEEnytmraFWjwaryLh+akjYDigAAJ6ihlJGP1oKsG9qnC8A0AQEbRj1pZFITkUs2OCD0qxLIPswBXk0AUoPvelTFfmyBUaDgnpU5yEBUZoAhnQFc5xVZeZAualnJx1xSQJu57+tAFi3gDyjPQVJqk42rFEBkdTToPlHXmqE3yzE5zQBatr2WPEa424xTJ2DSgDknrVeNvmyTTg/zZoAS4G0+5qGX5ogtSytvOT2pEG44oAVyFBYdMfrVK2yzmU1JcPsgIPU8UqoVtkROpoAcWL4yMGkk3A7Pxq01uoVOeRVe4yxDDoKAHQwMw3kcVoaS5guTIzKPTNEgZNM3p1asolvLG9uTQB0OrzJ5Jd2EjN3Fc/GhHXkdakxsAXcSD60+LPNAE0M/IUcGrbjPX0rJUlZwQeK1PMJUDHXvQBAUw9OJyQMZHrUrIoX3ptxGQEIoAfGBGdzcrVSfmTev3a0bhV/s0FT8w61D8j2OR97vQBSkbeAAKfGNiYIpiKR9KmPIBoAQcdetPiX5SW7U3KdqcrDmgBkIDTbj0qW6Ofu9MUlvGDOFPerGpxrEFVDkmgCnGvc0rSHotOx8gFMUDOKALNhA0sw+tegabp6R2WAfnIrmtBtcNvaup0tybgbzjHQUAcV4isrma+W3ijJLHtXa6Jpdv4X0hXlI+1yDpXSyaVb2cH9pXABbHArhNTvW1K7dpSRGvK0AJqF+8qu7nljxVGCCTYT3anoTO+GACrU/wBoVW2qeBQBANNUjdO+M1LbWFqhxvzmobuUt0Y1HGu1C+7nsKANuEx2yFYogcjrWU5nFyW/gPY1Zs9QdIGMq/Sm6bP9onkeQYUetAFe7OwgjANRW1iJ5N8zcUl1IJbwgfdFK0js+1eFHegDoLJ9KsE8ybDSLyAao6v4mlvJAkChYB2HpWJKF8zD/Maa2MYUYFAElxdeccKMY/WnRMWjwwwBVcL3qxF8xG6gAD+TLlDzWol68rRZPFZMkUjMdo49aN7wY3igC/44s0l0sTZ5ArgNLl8i5Ut90mvSbxBf6G3fC15qYdvmj+JTQB12rov2WOeDnjmqBLSwZYdKn0WRrzSmT+JRiqqkxh4zmgCvIdwAXqKYDt4705eMimhOSaAGMBncTzSgZbihl7mmxk7vagCwwzgjpUu4eWPWq2ScDtU+AF45oAjK5NLJIdm3HAp6rkZpHXI96AHwruXpSXm9YcKMUtuWRTUNzMWUgmgCkpLtirUabTzVe1BLn61bZTg80APMm0cCqcgG485NThty4NQMAGNACRDAO6kPAoBycCjrkUAIvzHFSgbZF9aYny896crNuzQBTnIeUA9BU8MiCUe3FVY2w7k85NPdlAyAc0ATyMTMSDxTAd4ZD1qMvgdeadGehPX1FAGrb3CGxNu/UdKy2j2uQ3PpU5wBkde9REnOaAFyOBt5qUA/w4qIdcDGamjGw8mgCBlCEluvWrFnK0hAPaopSCSKZA/lzDsKANgqFILU1nPPFKreYAc0SAk/KKAIXc+UUwaYRmPaDinsX3AEDaKGAJGAaAIVDKOcYpYjnIPSlYHPNIODQBLtTHAqMqd+RUikgY7016AJIlwd4PzCmSOXky5zUeSOCTz6U5Vx1FACu2cf3amtF86dRGMjPNQqwZG4rc8OQhFaWReB3oA27RFhhGRjAp9lMHvVYnAU9Kz3uDJKxU/KOMVHG/BYtigDovE+uSTQrbxt8gHSuZjPy5z17VB9oMk+GbgU+WaFXG5wDQBYD7RxwDSDH3j+dEkkbxqVYZpkpPkhU+81AFtI0uELL261Fbx+ZPz91ac2Lazwh/eEc0wSGK2PPzNQA29l3PsjPA9KBcZi8pQB71Vj+VCWPzml3YXnvQA6M7cqeSe9BfGVBpFwBnmm4yxIoAX5QOaTA60bTuyelK5x93tQAN93OMYpS2VGzrT4j56kHtUbcEqeBQBeWUNBgDDVVfc8bI4yfWmLMoGwuB70XkskUBeNc5HWgC94fuBGXglYENwBXMeIbNrXUXYKcHniokknW6WcP0PIrobuePUrHnBlA/GgDI8IyeXLIjdGqTUYzHftjoag0+B7e+G3NaeuKNqOOvegDHYHeaRuGFSZDAHvimSfeB7UAQyk5xTMnOKdKOc9fpTe4NAEy7QnHWpowMcmooyu/np6VOqgv8tADiNqg4NIxBwQcAVJnJ2EUk6LGvqfSgBkmNmVNZMz5kwDzmtJ7Wd497DYnvWVKo87C8nNAFuAFVyetTgNgsKjU/KAfSn7yo20AQtnODUbgg9alb73NNKbzwaAIkJBNPHXNNKlTzTgaAHduelNBOcCgkdKaDhqAKa8Cn4H500feqVQMc0ANYLinp8vPUU0sCAMU/gAAd6AHMwYZAxQ/KAjikKngYp+5duCOlADdp4NPUjdzTSePalT3oAf8p5qFlUuKnjQNyT8vpUM2A520AXYFZVG05FW1faMEVR0+UdGNaDFWIBH40ARnJzSLxncKs5RenNKY12FsjHpQBQkGW4qItg9KsvtLEqDmoyAFPHNADQ2TxQ+XOBSJ8q8daFLbSW60AMKtvwOacd5+UdaEJHNSA4+buaAE8ohVQffJro7bMGnGAH94wrCsxm5VnPPaux07S3vI/tLnaqd6AMPZLaJib7zdKW4IhtwWPLdqmvJ/PvWjkHyocA1UlQ3N2E6qKAK0Frcz5deFqdNDlmy8jkEV01rEFiWONRjvU00GAMMMelAHFy6fdWz7gSU7VrWQJjDOOla90oMO0jJrKcNH8uMCgCOVjI+ecelJIu4DB4pChzwalWNgQByTQBGIed8h6dBQY/MbjpVloxgIwO41fhs1ihEjfTFAGQ8JXiom9utbtxCGiJC7QKyki8xjt4oArtIET5+tVpJXYERr16VfkszJKATkCtG3sVAHyg4oAxLCKSB/OuCdvYVFqCXGoTEWoKr610d1bq0e1xjHSktE8oBFXg96AMOLRJJLb5mIkqS1MgR7SQZ4xk10QTBzVK8tT5m5Bj6UAcRfWs8E7KpPJ6VraSBHFhwd+Otat3pwlQshy4rLjSa0mIkQlT1NAG/ptva3ETt/wAthWTqA813jP8ADViyyL1XjbCnqK0tf08QwrdQ4bIyRQBxewhipPQ03uQTUk7CSTeOD6elRNw2etABwvbioX/dnd19qfKxxkc+1LGmeTyfSgCNRJI24CrtvaXFw42fJ9algBGDtx7VsWcf2xfKLiJuxNAFdNEmbgyD3OaWSG1037585xyO9RX1vf2cvlSSkxnowqhcM5G1fmP96gBmpXs9wCG+WLsBWVAAJOfzrQmdY4CGGWNZ8CnzcnpQBcBJPND8kYp6EdBzSMQDigCNCu/5ulKxBY+XSRYeXY3SpbuMRjan50AV3QjljzTCeKeThQDyR3pu4Y6UANBz3pwGeO9MGO1OjbY2TzQBVQ/KT3NBbnb39aSI4zkU4Lxz19aAFGN2KcT+Y70KPkzQvIwaAHxOxHB5oVNzHPJpApAyp4FPTj5u9AAem3pS5A4xSZByW4p6jC560AGOw6VHIVRTkZxU4XIyDTGiyPm79qAIrZ8/N2PatRCSg54rLjXyn2kfhWpEPlFAChirZ25FOjhe4l+8VAqVSMYZePWnbwqFU6+tAEpiVFIBGRVIxkk7vlHrU4bj5ic+tK2DFmQ8UAUnjMfT5h603eTx1q2Fwh53CqczbTlF59KAHiJjjsPSjHzAHpS290mQJBg1alRH5XGMdqAIrSFprhVQ5IPWu1+3Gz00Wz9WGK5XSBHDc+Y3Aq/c3YklLHlF70AVL99pKxHLsa19H0p0gEsgJduao6dDFNdGZvujpXTaRrVtHL5UmCooAiWKReccelJLE7HcN30rfS4sbpy6sAB2qdptPhRnkK5HQUAYVvaMsZln4A9a569kEtyQvABrU1rV3uGZYfliHpWJ9phXJkYe1AD2ATBJrRsIycSsPlHrWJPqFuvzFhtqlL4m2fKh/dj0oA7KB4Zrjc64x0q27RSSjccKK87PiXI+QHNRjxBOzc7sUAeiahOkkRSIAKPSseDKghxiuVbxHIuBhsVPDrxIzICRQB2VjamRsgEg1oPatCoJB29q5/SPE8Ee3dwnvXV2ms2GooFV1HtQBlzAMueeKhjDH7q8V04tLbbnIINVZZLSBsDFAGSNyj5lqOTLHI4FbH22yc7TtqT7FbyKWjYYoAxI4WdSIx83fFN1q1WLTmO3MuOlbCz2unlmJB9K5nVdWa5vwM4jz0oAx9A3XCSpKSso6A1tWRnmhltp23EDjNV9TthDLHPbcZ5OO9OOqrbsjBCGxzkUAcvfW7Wt66OOMmqxYDOOfatHxFcC5nWZBx3rOiZPvUAOhTa2XPJ6VdghWJ90n3TUFvEZW3dq0D5ZUCQ0ABUOdy02bc2CCQy+lL5gQYUUK4fjGTQA86nJNCbefnsGNVsLENo5prwkOWIxShNw+U80AZ+oHA3AZNVoBv5NXbr5G2uOKbEiBcgjntQAyI4bAp8gBphI8z5fyp8qnaDQBABtfPerMnzp7VEMd6erBlIFAFduBio8ZNPfg4PWmg9aAEYD0po607j1pvQ0AVyCxG30qRUfHNLhNvJxSJIc/MeKAF6cUhHymneZk9KXcrHBoAImIjwasKAY+TVeViAAo4oIJUDNAD0cAlTzT8/NtXkVGkBHzE09Y1U7s0AEWWlKg1LysvrSwqoy3emlvnzzQAt3ZtGvno+7ParVmC0QLDmq9w8aRAq7Fz2NWrN/3QyMUAWRCzDO7gU5Ldzg9hSCZQNpNSiYuoXoBQA02zMeTxT1t1H3mytIEZhtVuDTZEdMAHNADlt0Lkq2FqvLbF3YLj604Ru4+8QwqRA44JxQBmT2joc7CfemW4kjkUk5UnpW4JyPlZQR61m3wEcm9elAGvZWglXfjA70y4CrNsUfL0xT9ImmmjG0fIK0LyJBbFlT5+uaAKsVvtjHO3NQanpFxZxi6hZnTuBTo5na3fzOCvetnRNXgFi8dw6soHegDItbkyQK+4q3dala5baPNYkVXlu7eaeR4U2RqeTVON5tSm8ixRnXOKALFxeh/lVcD+dVV0S81SQfZ0fB9q9S8C/DOadVn1EFYxzg17Bo/hrTNMiURQKSO+KAPm7SPhRrF+QJQ6xmux034FFEDTyEqeua9427MeUAg9MVMrOVwWJFAHjlv8FbBcE4NXYvg9pvqterqy9DxUkUMTnlsCgDyN/g1pzNlStZGqfBlWJ+z9B6V7p5QGVUnA71G5kU4XJoA+WNb+Gl7p+7COUHpXKy6RdWLkxeYrDnFfZssMMqlbmMPn2rndV8IaZfbv8AR1QnocUAfLlvqWpOnlRu2Rwc1Zh1hoVaO7GXr1/Xvhi0bM1iQCecVwmueAtRgVmeAk+ooA5tLuNiXBIJq3BeSAYWU4PvXP3dndadI3nRPgU63vEkGOQ1AG5cyMwG9sjrVMrHLKGPABrMv7i4t0DKjNVjSIbq6haaVWVBzQBrX10rmFU+6uM1oXctle2kcaxbXHU1jWsKtIxzkClnl8tWKjGKAKPiO3jtghQjHpWTDbBmV88HtSanJJcy7ixwD0q9Y28iRB2GVoAm8o4Ai4qTZGq/McmnBgeVGDUEiSOeKAJE2svqaWM54TrTI4HyScqKZ5bhiyvxQBYkHykOarEhVOw80GbsxzQHTp60AUr4ExhiM1PBp32m0WWM4YdaLlA0XtVy2uFgstsXPY0AY08ZjOQfmHWmmRyozVm6w3zDvVbLYxjigBqksalhJLFAPxphQLgnvSxny5gx6UAEoEZKt1FQsM9BVzUB5hV0HFVd3zD0oAYq9aOM08PlunFMyN1AFNRu+bvU6FQORUGQDxUqt8vvQApo2Fuc8UBST1pfunjIoAUJyKcpUNjnNPRRjJNNGGJoAczNkbakUgsBUSn2Ix3p8Zz3oAslEU8HjFNWIvIpTpUJJlO0dB3q7b4VeDwvJoA2L+40mPQhCIc3n973rDslKW+ZeSTxVW7vPPugip8o71pIP3S4GM+tAD/LD4c02Ry3CDgcVYgjIU7/ALvaondQxAxigB0TMiZqaMtMu9+CKrOxClh09KBOzR7R1oAtGUbR8vSntOkiBQMVDA4VOoNIHG/lcUAWIYsk88dTRPCLlWUDgUxJN7bAcCrjSLbIAMEGgCDQZx9oNrnDdBXQagRp1kyuu4t3rjL4Pa3iXcX3eprcOo/2nbJk/dGDmgCr56rExkHytTrPw5JrUqNZTCOEH58nHFTW1mb6ZYoxhAeTU2sTGwdLLSXIkfh8UAXNe0618uDSNFUy3XAdwM16/wDDrwDaaJpUM11GGuZOSDVT4VeEI7OzS+uk8y5cZJbmvUIyMAbcUAEaKqAIu1R0FSbu1MJKNSnmgB3celKZliO1Oc9aYTsx6GiCJQS/rQBMhA+d14ppcHO0YFNlbcNueKaeAAOlAEiTsDhaspKMYPU1TI2r8vFAfavPWgCeaIr8+c1Gtznhlx70+KQbME/nUMow2exoAcxVs/Pz6VDc26PGd6Bl707YM57Gnht3y5NAHK6x4U03U4WV7dQx9q8W8YfD6bTZ3ntUPljngV9HSgIelZ+p2SXcOyQDDDnNAHy9o19aNc/Zr6HO045rY1e4t5I/ItFVFA6Cr/xL8Jf2Zdfa7VeM5JFcO0d5epixjZm7sO1AFuFRGrJu+brWXPduZTGfuitFYvsVvtuTmbvWHOu2VpD36UAOMa3E6oh5rdDm3hSNxkYrD0uMC481iSe1bqN5rFpOg6D1oAhkYSMAFwO9JPMIcKi5FLI5bcAmPSqTD5jvfj0oAtvOzQe1Z7vxgdKVnbaQMlarPLwcjHtQA58gAr1pQrY3d6qx3BV/nHHapVugZMKc5oAnUgdetUmnMV4AT8pNWX2kg55qpqSkxB1HI70AaE2wqOwNUXDRt8vSm2lz58Gxj8wp4bcNrdQaAG7wfvdaRyHQZ7dKWRMGmEEL7UATxM8kRGPlphVdvPBFWNOPmK6j71Q71WVkkXkUAV9jbuDxSHPQ1aJTnPSowwQ5xkUAZ6YyCaccFsjpSDg4pcUAPXPXrUoUtgVHFuLgZ+Wr0ibACKAK7KUG31puMYFSbtx5qIDLnPFAEmflxigBQODSLwhJpq4NAEsY/un60t/ceTb+XGPmNLH8gLngY71Ho1jJrGrLboTknigCtp8TuweQ4Oa3pZBHGijrUfiq1XQ7tLRSGkHUisy41JPLCquZMdR2oAvz3RIwW2j61WeRAuRLk1lRpNcHjJNWBp1zjJU49qALMV2AeW4pUvgk2Sciqx02bGehpjWU+7GKAN6IxXH+rkAb60slvcIST8w9awnt7m2AdOPpV611eQbY5j+dAGlBuA3MCMVZVjKvydvWkgvIGh+UAt3pvykkqdh7A0ALcjz7VlYYIqnoLmO6aKQ/J0FSFpEfDng+tVIWMWpKW+6TQB1ui3aW2onso7npVvRdMj1fxkjx5wG5x0rl75zHKHyQp716l8GrVZNQ87GfegD2+ygS1t4YowAAoHFTOcSfL0pcbZhuNEmATyKAF3726cCnPkjH5VFFkHOOKk3deKABSOjcmlZtqng1Hg5zQ77uDxQAmc4NKX6AUzqMCozlWxQBYLE96YzAjFID8tNJ5oAGc7gFyMVZdw8PHWqZ5birMTgKRjmgCJGboakU/MPWomJ3HPelUlaAH3BBGcVHKwaEDvSyMSvSoFOSc9KAMDxzpK6n4emAQBgpya8O8P6kuhfarUxAnkZNfSLoJLaWNvukGvmjx1aPa+JZlUAIxNAHPMZdR1aYscgtke1VtQiw5iA+atLTGW2vHZqyb2cy6qSvAzQBY0+EqhDAAjvU32pYHAY7qoXl35eVVsN/Oq1olxfuUt0Znz1IoAtapfBfmVwPxrJXUGckxBnP0rqR4Qiit/tWszmPAzszjNZdxfWiZisIMIvGcdaAM4zX0iFljIFUpIryVvmyAK2Dc3TLgBQPShVkIJc4FAGKY7s/LtO3tUaGa3Y7lNb0YcHqCO1PyuT58YK9+KAMmC/BwG61bluYngIByfSnXmkxTx+baEZ9O9ZBtp4T86kDPWgCTD20qygfKa0iRIFlXB9aznl3RlG5qTTZSoMTHg+tAF6Q7sEVCxwfUVIw2Ns9aTA2cigBquYpFkiOBnkVZvk3qsoqqwHlkA8Ve05xLAYpB+NAFHIb5fSkY44qzcWrRZYdKqHmgCOBd+c03OGwelSwZVTtGfeoiDu55oAmtFAYlz9Kndi3GetUgDvznirGCSGFADWGMgHmljbjBHNDrnJ6UkRHTrQA5+UOKIlwvPennaEx3p1oMyFm5A6D0oAr3rmKMq56rwK6X4UX2n6frEk+oKSQuFPoa5TUHWaY78qF6Vf8MziLzd8JkJGBxQA7xPepf+JrmUuTEznb7CoYdLSVy0ZOz1p1hZ/adQZ7xfLQEkZrTllViYbddsY7+tABZLb2cRVQHkp3nyM4DKApqHbsC4Az61KRlcmgCObcGySMdqack9qR+RknpSICRQBIVLc8H2NMa0t7r5Zl8uQfxDpTogHXk4apBJtj2yLuXt60AZ0trcaXKJV/eQ1qwkXsQuEOAO1SRtvhMMhzGw4z2rHWWTTLooT/AKOx/SgDTncMo4yRVK9GIllHXNXRb3Elubm3iaSDuQKzZrgSxspBXHY0Ab6+Vc6KWcfOBxXpnwN3QlzMeD0FePx3HlaeOcrXpHww1cRvEc8E4oA+iJPvZ9RTCmVyzc00SiW1ik5wVpsucDmgCWMkIcHNCsSDimqwGB+lK3ynK9KAJVzgmkIB600MSMdqG6UANyNxxTDktjFOC85B5p3IbFADVXb1qLJZiBUr1BGT5pHSgCQDacGpE4JPamv155pVJP0oAbLyfloQMFy1JyJBnpUrHdx0oAjY8VAAXlyeFqy65GOlQyAqgxQAKDhy33QOlfOnxHYyeI5MfdBr6A1u7NppbyD7xGK8C8b+U0E12zjzM9M0AcZLLskIT5jWNLKY7nCjfPIcBRWjp0yi1nuZOw4zWl8MtOhvdXm1bUlHlQ5ZFI4JoA0tD8BuLT+1Nal2hxmOA9TXZRWOm+GNGOpXkSxvtzFGeprU8G2Z8Q6zPrOtS+XploC0UZ+7gdOK8x+IviNvFPiqaOI7dPgOEA6cUAY2s6vPrcz3V0WjiydsQ/Ss0DKLldg/nVkjzXZzjYBgCo1GRuJzjtQAqKQOTzSgnPOTQx/ChWweOTQAoKg9Tn0p2GPXkU18YBHB707fhBzzQA0s0bh04A6r61fl8u9twyKAw6g1UbGA9QyTMv71QRs5IHegDM1dIIyBDkPnkVUQiKZGGSc110ui2uv6Y11p7hblBlkrjplYNtOd6HBHvQB0s8O+3SUDtVF8q3HIrZ0djNp4SVR+NU7uzaJ9yg7fegCoRuXp1qK3LxT4z8tSs5UgMKhl4O4UAbEbCUbX6HvWfdQNEx2/dNPtZd6AZwadJMApWU8etAFS1+4wXmq2DvYE4b0qS0m8pvrU88BkbzUHWgCug2LlqvWwUQF2qu0WUG/gCkkb92EU8UADHcCR0NG0IAR1NN4RQtKjDqfwoAlija4YBB89a5+x6faMJTm4I+7VO3YQRmbgN2rBu7kyTmV8k0APuZ0mLAoAxPFdToFzbWWn7dimc8ZIrlLGI3NwCw4HPFbpjEcilOeKALc7h1+YZYnioiDgDp9O9L8v3s80w4J3E8UAPweM0OSFJJppZSM7uKHIKdcigCEEsCR0qWEDbzUQz/D0pwPPfFAEiDDZxU8YyCf4hTUGRkdKlVRjPegBigMrEnBFLHbw36+XLgY71IFUnJ61VlcRSZjBGetAHb+H9YsbG0/s0RqwIxk9a5fxstpg/Y0CN3xVbS7hHvM4APrS66RJPheRigDMhYSWKp6da6HwzcNZvC6HgNyBXN25Cy+WwwprofCoDaqtpJ91zwaAPqPwzef2j4ehkUgkAcVp4VoRk4Nef+FtSfw/fQ2dwP8AR5AAD2r0KQIzjyzlG6UAR/KMEnipjyox0qLCh9jnA7U4yBTsBFAD146c0mRnJqF5dp4pVcMM5oAk3BenWkDAjJPPvVee7SMc1X+2xH5nYCgDR5PORUbgA5qt/aFsqcyL+dVLjXbeMkBlNAGoem4HIpytgViRa5BIQQwxU0uv2+AuVoA0myTk0JljgVRttSgnOEYe9XklGcLzQBI+QuKiJIUKeSaGkOeelVri7jth5kzADHFAGJ46vFt9JdWPOK+ZvEt7Nc3boCShPSvTPiv4uVlaKJwe2a8gineXMj9WPFADtQYLYCKMYLda6vw3dQ2ugpAP9YTzXLXILR9Rk1LayvFEOOBQB6LrGvtp3hBrW3fBcc4715jZI3lO7ZBY5q1qN5JNahXOT6UtuP8ARgTQBEuFXHYUvHYUpHBPao2f0FAAOetLgdV60gb1FAlUNhRzQBIuCPmGDSFVZSOlRuzHr0qSHGOTigBsZ2gqelPSMszDPBFSfIFOOTUe0Bs7jQBVs55NOun8iQoG6471j38ubtmXqTmrF6Wjud+SVqrdsHbevGaALdjfXG8BDyO3augTVBJHtmX5hXIRSPE+5D81SC4m8zczZJoA6OWaC4BCjDCqFxEce1Q2dygYO3UdvWthJ4LtMgBW9KAMiI7ehPFWZNp2l+U71DeKIZeBTgm+LOfloAgyu3n8Ks2920KYxkVWPJxS4wDQBsyW4uLEypwMVkRqeT1IrQ0jzntpVU/KB0rPRWW4cE96AFkAYr/eNWo7ZSFZ+gp6+TGu5h81VLi5LggHAoAbqc+V2qcIKynZiuMcHvU9wCynLZFQt0Xd60AdVottFb6ez4zIw4qujMrHcMsTWlZMI9NV3U5xxWYknmzM7D6UAWSAQMjFP8uMDOeKjVg7fMOlKXGMAUADeWTgCoT0KqKlb7owOtIzlV4HNAEaMVUr3pUbA5FJ16dTUsMQb71AD0cKmF6VKjDHy9KYtsvY04xFDweKAJlAJG6ob5ABle1SZ+Wo75hHb5PcUAZkD+XcjnrVu7OWDZzVSOPKbugNPvGCwxjOaAH7Qzq5H3ea0ImvLqZJNNiKSJzuxVZQzCMkfIOoq/da7NFGkNjEIwBgmgDZtfH9wZobDWYsSIcB69T0Px0bGOJLkeZCeA9fO92v2ubNwMyn+Kut8E6wkE4sdYAe3b5Uc9qAPpew1rT9TVSs6gkZxmrrNFvwXXHY15JB4auUT7RpNyZIiNy7T0qsbzX7UOtyHwvegD1m+vbazUs8ynA6Vyeo+OrO1crG6lq8z1HWrq4kZZZGXHY1zk26W4JJOfWgD0678bCRyydKybvxVNLnDEZrlI1bYFHNWfL/AHeNvFAF99ZuWJPnNj61Vl1W4Jz5rfnUNvbo+Ru59Kgurdg20UATnXbpQVWQg/WoRr14OC7E/Wqklk/BapYrIl14yD1oA6bRPE8iMqyFs+tegaPriSqGkn2r35rzGWwKW4Krtx3qrEl7qE6WdgzZzhitAHs174ltxHstj5jiuE8Z+LEW0c3EpSUDCqDWb4g1W28F6WIQRPqMg5yc4ryu7ubjUZjd6i2GbotAFS8muNWvTLcMRHuyBU6oS2B90cCnAggDbipInAbaRz2oArOwVyrdqnSRmjwBxVcozahtfkVYY+Veoi9D1oAiuFxbse4qxZlmtMmjVXUDZD1xzUOlSfKVY9OtAE+GKkUbCo5FOija4lOAQBUso4CHtQBUKgtg08QJjIPNMddtNZm2gdqAHEgHBpwC8ZPFRrIu3GOaFXdz0oAmYKBlaRGUe+etNSXd8hGPepGAjT5O9AEF9Ygw+ZHyT1rFns5MZTkd66DzHEft6VBJC7DMR560Ac6sTsdqrzRjyzh+tbHltEd0i5amTKk7AvHtNAGaqtuBQZHerUMjRyg9K0YbFTH+7aoZrZEUk53CgBt4xkUNT7RwY8GmRxloSW5Ap1mPmOOBQBADlqeuC2DRjvjFA+9mgC5p0/2YuGPDdKgUbrpsfxGhYmlIxV2KBYF3OfnoArXimJTkfjWdFG0mSQStad6WaHLjg1Z0uxklhHkAEGgDOa2YQZEZZfUc1mMhe6jVQc56V32nafc6W3n3Sq8B5Kmore1guNRN5HDti+lADLqVI9JjiC4cCsuFVKjPHeptVuYzfbY/uelOjVcEgUAQM2Wwo4pdygZHWnGElyQeKasIzg0AKm45Zjx2pjAjJB5NSM23CZpGPGAv40AMi4bJqVWJPBqPoKQA7qAJ1DBuDxUr9snrQmQmSKVV+ViRk0APVM4QHk1n6pJuuY7ZecHmrcT+XG8hPIFQ+GbZr7VXlmU7M9TQAavHBZ2MWHHmnsDVGSENZrLvyev0rtNR0fSJdxaTfKvYHpXF6kFty8cbZXoMUAXfOY2asvaoZT58SsW2kVBazFbY7+RWlbaa0mntclsoORQBQH3cE/jTmYMiq/G3kGmhQ6/KeBTc71CuOOxoA9V+FPj6PSlNhqLFomOAzdq9C/taPUbpkiCzWznhgM4r5sjVdjI/Q9CK7L4UeJ20HWxa6nIXspDgMx6UAekeK/C9o1uZrdhuIyQO1cNLpr28TtJjA6GvQfEt4guA9mRLay8gqa5+/hY25WTlGGc+lAHMadIoYsy7lqxeSGQZhAx6UxbZbdin8LHrVu0sFU7mbKnoKAKdpE7SDANX5rYo4aQVaC+UeFwaa0nncP1FAGfPGZBgCo4iYSB3FXiUVsA80NErAEfeoAv4kvrEQjCr3PpVLUNRXwVp8klsm+4kH3utaVrAfKBZ9qDrXHeP9WS422luNyjgmgDirq5n1K8k1G+dndjkBu1PVgVDv83pTCoChTTkXJ+UfLQBKgHLNSWirNchSQD60rkOKrKuWYjKkdKALN0n2XVAAQ+fSqt4xTVI2z941CjsLos7EkU62DXmrIcZUHGaAJdXfyrqLPRhVZ91pMkhOI2rW8V2wMKrGMuo61Do32TUbJra8bZMowuaANCGZVjG3G1xwaiYbXyeSax4na3uGt53O1T8pq3JcJjAbLduaAJ5kwucYqu2ccGo3vgFxLmhZFb5lPHpQBKqE8j8akVQeaYjEjKnrUseO/U0AStCjICDz3qCXMeAvSrCIAp55qa3jSQESEUAUkfIzmkH3uDg9alkiRXKp0qBiqvjvQArLvPzDmmyJnhRhamV1I+bmgEZ96AK4BhIIJANOnKPCQByaklXcCCKrk+ShI+agB39n+Rbh/MDA9s9KrAbJMDin2YeabdvJXuM1NLEGuFxQBCU568U9YRjNNB9elSguoyCMUAOHygbODS7Wc7mOcVEOT1qQHAAPAoAcUEn+s+5jpRo129jdmMsfKY4FMkuQB5ar+NVZyVX7pOe4oA7azgu55ma5kL2jDj0rOuru7trt7aNALY9MCqWm6/cadZmGQebGe/cVsmZLjSRNABJdE8D0oA51bQtdF512EnjPenK7pI0brtGeDWlqNjey6X5twQsw5Uish9/2JTKf3o60AWJcp0PXtUsQDx7m+XFUoZwyJuOWq6zfuhxgGgCNmjkyQMkVESTwRinMyxjiojIM57UAKFbcCelScbhVaS7jXPzfNVKTU1AIwS3tQBvBkX5pGytUrnVFEgit0JB6ms+G5nuFO2Mj2qQTJDbM1xH+852gdaAJLq48xlgRhlutTR6nJpsfkw4O7gkVpeEfB1/q1rJeTxtFF1U460//hB9SE7sI38jP3iKAKdjeRsshkfEjjuabBod1el5Yjuh7t1rr7LwpocdgTf3DLOOwrPjEmnyGPTJC9tnnPpQBz1tp6xmSFwcHrXX+CbGDV7WbT4JV81QcAnrWV4gtz9kW5tvvH79Y2j3EunajDeWUrJID8w9aAJNVsJdK1OeyuIyhB71UAB+RuMV2vjKWbxBDDdJEvnAAOVHNcfcwtE6q/Dd6AIU+bKjkipEVWwsn4eoqLARwyH604vulXjigDs/Cmr3Uci2rsZYc4AJ5FdzeRNNAAO46V5PbNKoWa2bDrXfeG/Ea3loLe6IWccD3oAgmhaOTY/NaNjJCEKyjL9qma0+0MRL8pHQ1BHb+XPtkQ4HQ+1AEMzPHISeR2qKKOSSQv0BrWnijYAKRTZIRbwgkjmgCoYYwvTLVJaQEvnGRmnwWckp80khKvpthgaXH7tOc0ARazNbWOmMZmw+OFzXkF9L511JIowmc81u69qj6jqTjJMK9qwr+WMsBCOO9AFSJCWLMDipC4B4GBSqMYb+GmvjqvIoAYfn+YcAVs6Joz31tJKEY4HYViyEyx4XjFdfpHieLRtCeBIw87jFAHHXtk0d26cipbdfs6YiHznvTTcS3U0lzP8AKzHhaiDsWOeKAJp55niKOdznvWTJGI2LAlZR3HetQZ2E5ye1RYDA7xk0AUVuY5cLcqd3940uIFfhjn1zU0lrHJzVe5tvl/d54oAmlsL2OLzgm+I+1U7W4aCUhhlT+lXYNQ1CODygd0Q65ps8AuoC6Da45xQBbhlG3cv3TVhPmXcDWLYXGCY5Dg9MVtRHKbVFAEyAkdcUuTuGDxUcZIyDSgMOW6UAJK2DweaAFK/MPm9acgQnJ6ClJVjx0FAETLjtRGuBup0pIHA4pryhYsd6ACSYAHkZqkWYyZXkdx61G8u5yKt2qcggZNAFRJDHODGCPUVoLcIzKBjfVe5kUSEKvzd6hTltw4IoAezKCect2Aq/Y6XJcJ511II09M0y2iihG58NJ6VLK5lHzyYPZR0oAglMYcrEPlHes+e7OSqDNOu2kjyvY+lVoU2A7uW96AFDODuNSQyy5JYfL70gGT83X0roNF0uD7GdT1lni0tG2qiHEl04/wCWafpuboo9SQDnVqxpR5pf8FvshpXPQvBfw00a48PS6/rOtrd6fEjSyRWYKgBRkhmYA59sD615hp2ofZtRmFsghjkdmSLcSEUngAnk46c1pX3irUpYNQtonWGzvIkgNvGMJFGjblVB2wc+pO45yTmsIWxkRWXhgck152XYbF06lSpiqnNzNcq6JfKyvfS/kVNxaSijrFuZgwSb94jcn0FZ+rQW24LayZYnJX0qQXiyWSW8PEvQtUVuLaG5SOQ7pieTmvVIMySMIR8p3DrTJLmRyBFyorc8RMsaLHBEMt1OK56a3e1gLhx8x6UAMlklYZJ6VEkkkzeWhI96tWUJky7/AHD61amSG3jLxj5/T1oAy4tPlu7kQxZMnTIrobDwncCcRS27iQ/xEV3vwW0K3mE+q6ogSOLLYbvXP/ELx1PqGtT22jRiKCI7d6jmgCG98HatFsiSMJG38fStbSvhtc21zFc6jIl3GOdqHOK5vRvHWoh47DWpi1u52+Yeq16lHdDwbZwXsN39vtLgZxndtzQBJL4gTS9ltFAq20f/ACzxg102k+JrHxVZvZwW6WzRrzkYzXl3iyzv7vOrWKGeOXkInOKs+C4p7OKSTVCbeaRcr2xQBr2i6Ydaktbq2afaTkqKjSPSL/WXsNPt2ibpgisyLxEuhTXEyos8z529ya2vhZew3OoXOtazEtsFyQp4zQBxvi21Oj38kDZ8s9jXJbI0mYD7p547V0vxI1+HX/EUz2i7YkOB781yzyAMSPoaAL9jq95YTeVGRJAfxNLqflTfvQcse3pWdBlQWHGant2BLBuaAKrRbOe1IoJICdT1p02VfGeKltSokHODQBoW0XlRAnP4UkheOSOaM7ZFPGKnmnzbfcI464rOjkaRiW5HagD0nQdb/tGyVLlcSrxx1Namo3Mf2dQRtYVxPgebytTTzwWjzXS+Lr6BpAIiB7CgBXlLxgg4AqC9u5JEjQEcVhJdyOxUHCCoZ55fPUZIAoA9D0/5bNVkbEJGWJrlfGPiNFtTZaXyvRmFWLvUHm0UQQnBxye9cFMGSUhuDnmgCezizCQWAz94msq7i2zkL92rjvyAjYHerV/bRtZh4WDPjkCgDHDYGKFOWxjFOSE7SxOMdqRjk5AxQA35kfAHFJIQXz3oYsfTFIVzgmgBpxv5pGK5zQwJbimyemOaAEJxyD1poJJOKVAB9achAYg55oAZg5qSOMk4HOaVVJbpk9qv2MGyUM5yewoArXdqIISzNhvSsa3nllnOTgD071p6iGur3ymbAqrHD9nuvLHNAFO9UeZvHB9q2NLmWW3wThgKo30OZcDpVayk8q42EkLmgDok/egjGMelOWIqpy2aijnCgBe9SmQHOMA0ARHlTjIpEHGKXazHrQeODwaAI5HK/SqMsvmOcVZmfkiqEq4PofagB0ShnwetbdpEY4SSOvesezAMiKeWNdPPHPDYDMBII4OKAOduEImYjnNQg4BzxVu4Qxx5J+Zu1U+3zUASxsy4zy1STOAcgZY1XVsHOc8VKpymetAFWQu0nztnFOXLOCetLjLE1uaHpcC2p1XWGePS0YqqKcSXUg/5Zp+m5uij1JAOdWrGlHml/wAFvshpXHaTpUAtjq2tF49MRtqIhxJdOP8Almn6bm6KPUkA1Nb1SbVrkTThI4o18uGCIYSFB0VR6fqTknJJNJrupXGrXQmlCRxIvlwwRjEcKDoqj0/UnJOSSapDaFANZUqUnL2tX4ui6Jf593+g2+iEV8HI5FaMU6+SQy4T261QKbV3LzWpo720U6NdruUn7vrXSSZxuFY/uCRg9aqzSFLpJ9xJB5rvvFGn2UmnJPp1sIQRzxXn9zHjjmgDqRKlzaJOzjb3B61lXyefIJIFZo1ODxTNJYIgSXJU9q9D0TSg1kpWACI88igDgY9O1KUrLFA/2cdTir+m2Nzql6ltDASAeTive/BFhpdzpk9nctGhKnGcVB4c0IabcX0iwp5SZKuBmgDlPFOn6h4e8GjP7uN05HSvCFnkUPIHOWY5r2HxD4nl1xL+wvJt0ceQqn2rx5ojG0sZ6bjigDS06zGo2b8FnPIr0zwC8UukzaTrLFY2BCu/8NcV4YjeK1LYCn3rQubuRo9snDf3hQB7D4Y8N3uj6ZILC5S8ibOwFs4FP1nTba28OyT6s6/bmzsUHoa84+G0ur33i7TdNh1CX7JJJumQMf8AVqCzD2yBj8ah+IL6zoOv3Wm388lwitvhkb+OM/db+h9wa5PrtH6z9Uv7/LzW8r2K5Xy83Q29Is9FsbCS81CUT3OfkU/w1yeva1LIzCJ9seeFXpisL7VLL8u4kmmS47nJrrJGSNvyQMMec0RYC4frTdx9KQ56npQBIvzcdBSoxBwvTvTOW69KlXCp7mgBJAGIC54puFWRD6VZtofMGF+8anltBHFtIzIaAOhS5t9Q0hYFjVZFHWuc+yus3lKcnPamWN01tIEfOSeldnp2n2y2wuXOXbnmgDM09ZLWICMZcmrsgiWIyXT5c+9Q6lexWgIg+aU9BXR+GfDA1W0+0X5K5GcUAcigIkLg/L1HpTo5GnuQCPpium8Q+E7uCM/2eN0XtUHhbw/LJMPtP3h1oAptFPCR2UisDWLU796ckmvVNd8NvDaCeNtygdK4C5ETSlC2JB0BoA56K2czKsny59a6HWPBepadpSajbFngcZNP/sx7u33nCunI96nk8b6j/ZL6RcxERoNquRQBx6W7CAzTuAc/dqtKwYZXGKeDvZvNkJ3HOKsJarIhCLQBSK4Tg1EQR34q7JB5Q+eoMA9OlAEOB2zSEZ+X+dS7ecjtTtisctQBAUCjPX6VJbwNO4UKefapUkit8nG4+laVjqEUgIaMRt2agCnfWx08Iert0FWYYjFELiQ8ntVqfY0eZf3h7E1mTyYHDlj2XtQBW1aLzJlnjBDd6rdGEhyWPWtK2uEkJSUfMelR3lqYPmPQ9KAKUgV2yTzWXdgJMCK1toJLetZmoqN+aALlpLkKW6CrxwwypGKw7OXnax+WtS3IzgnKmgC6qKACrc1DM2AcmggIpIPFVzICSaAIXJZuKjkPIJ60O/zGkDb2OeKAJIS0UiSAEsOgFdPLrurf2eEayzFjG7FYmkKTcAsMhegrevdZumi8gIoiAx0oA5iZmlfe5wW6j0puQo7Gpbt1Y8L+NVwoHJNAETD5sg8VOZPLi+XvVcDgU84Jx2oA3dD0qD7IdW1kvHpaMVVFOJLpx/yzT9NzdFHqSAa2s6nPql0ssyokaL5cMEYxHDGOiKPT9Sck5JJqnc3dxcJbxzzSSJAnlxKxyEXJOB6DJJ/Gmo5jkBPQ1zwovndSpq+nZL/N9X+g29LIV8qoHakbsDU0mWcNzt7ioplBIIPHpXQIlI/d8GkDLE6SHllOcUkeNuDS4yjDsaAO2uNQl1PQkDIsUaDt3rktYt1lt1eDovFWdGvfLRre5YmIjio5WWORo1b923SgDJgmeMxv1dT0rrD4tvmtIoUGwrwQO9ctdRYkwnfvUW9oJkbdlhQB6np5OpaSJrG8MV6vJQnGTXpnw81ptN0Wb+3h5qsNpHfFfO4v2jiE9u7JOvTFd54E155QTqDBiRja3egDf1bw54flvrnVLGbAb5jEa8c1+KOTV3FuuEziu78T34t7t3hGxG42g8Vw9w26680HmgC9LcrZ6esQ5kPepNKuo2AivBkv09qz5MMMsMmoUbEuO9AG/petX3hXWZptLKrPPEYVnKbzGpIJK54zxjJz3rc+JN5qOsa/cRXE/mxQSubfco3JG5DBc4yQBjGa53w3qMK3nkaggfdwrEdK3/HczW2u200Q/czWsDA+4jVT+qmvPnhqKxkKziuaz1tr06+l/wAS03y2OVSymjcbgQD1NMuYQH+TnHWrV5qjuPLCYB71Vjk29smvQIIGU54puxs1MXUHAHJ5pC+3mgBYxxUkcJJy5A9qiV8cmoZDK0mWY4oA11nhtY9ykGQ9qb57lTO4OR2qjbQK0hkdst6VeaXeoXGCOgoAo3E6w3iXDjOTnFdj9uM+mrLHHtVRyK4OZ/N1FEfjB/Ouxl1mzGnraIAHIxQBB4fi/tDWlzluele/aVZxLp6oF2nbivCPBlwltrabyFBPWverK4DpHsOUI6igB9pGDDJDjPas220r7JdOyqDmumjtI4k3o33uTUMAUyk96AK8luj2EisM/L3rwXxzALfUHMPysDXvmsXa29nKXAUAV8++L7r+0NQcpgRqePegDT8OapHJphWYfOorC1rVIL0vFEgVl4zVPQ9U+y3RgnTEBOCcVe12yttn2nTiMHk0AYtrbRmNi/3hViOZ4Vwi5HrTdMPmq7MORT0YBmUcCgCCZjKpL1UVQBgHFWZNw3DqKqgHkdKAH5UYApJgnGSaVFHWmyEFulADNucYGQO9FwdyqDxipE2gU1tvIIyDQBPa6igi8qX8DUE7qHzGPlNQPEpPTinpgLjPFAE1sqNKN/4GtK+t5JLcPnKgcViqcMM9BW3p1z5kDRNyMdKAMdF3A84rN1MBfrWxMnlzsrDA7Vl6qoAJJzQBmxHDZrXs2GzgVjxcgVq2hCp0oAth89R8vpUcoXqtPL9MDioJCSelAEE2KEQyYI7UjYJ+arFmdrgDoaANjTVCWjyPwQOtRwyJdK5VuRVTUJGjh8tSVDelR6ckqSKiRthu9AEE+Q5U+tNI4q5qcAt5QGbJb07VTYEHhqAIV5xQPv8ArSn5U96agIXPegCTcGIqQkYHvUMfXOOKmz3x9KAJrGVhJgqXU9VqzcLFgkRMjnoDWj4Mks4dRWW9xgc7T3p/jXVLTUb8Lp0QjVeMqMCgDnEbG4HrT1JUDNMyQwGOfWl/jGeRQBKxw6uozU9yg+WRutQo3zqCOOtPvJNzBR0oAiZtw6c1VkiUyAnOassAFAzzSlAcYPNACIDgA8gVZt5XgkDROQ1QKNnPrT12k7j2oAsXF1dXDDz33AVESpbjrQreZyvIFInzP8o/GgBX4puMnPQ+tOfk4pit82O1AEnQhlHzjvXS69O11ofh+WQ5P2V4m/3lmk/9lZa5pPlet28Pm+DtPYcmG+uIz/uskRX9Q9cuI0nTf97/ANtl+pS2ZmtbPcKpjHAqOVdp2jqOtX9KkAiZR1qlcjbK3rnNdRJXY5YALg+tSKmeDzUIycnFT2xLN7UARyRkNikYfLg8471LOct1qMZYkY4zQBatrfERfPQcUtsclpH6DvVvyD/ZrGM8gdK56TVHW2eARnzDxQA+3sbjW9VdbEH5f4qk1HRpLG5jEsh8wda7/wCEenC3sJ7u6UbmGa5/xIgutXmdScA0AFpaTG3WdeCveu18JeLjaOkV0xZAe9cv4btL7UZvsdt8wPUVq6n4YuNNIEhy/XFAHrcPimylgBSYAnoCaik11LdDNIQqdQc18+6lPcw3OyOVkYfw5qVvFF7LbraSkselAHceLfFF5qkzR2DEx9Dg1xxWO3Ja8k/eHnbXTeENBuJ4PMY7Wfsa2Ne8IabZWLXl6+65xkL1yaAPL7l1Mu7b8voKsfax9iKlWUY4zUlsFub4qkR68Cu0TQYbzSWDxASBeCB0oA82025MUjDPDGr7Rnd5in5axLmA6XqzxSEshbjPatpboQoG4aM0AQXDELyMVWzuPerl2kksXmoPlqojYxu70APwFGc5phXJz2qZhhfaoG4GQePSgBrDnjmhxgA05MHmldsjAoAgOSKei8c0wNhuRinxHc1AD1TOafayGK4XjApu4iXnpTbnORt5IoAs6qDkP2PesfUBmEE1py3Hm23lv1HSqEyZhCHmgDLhUkdOM1pRgKnWqiArlQKsLkqM8UAT4YrxUbFh708s2wYqIkhcnrQBC2M89a0dGVJJG3DpWY3DZ71qacPLt2cdTQAmo4e4wp4XpXTeD9QspI2trxVDHgE1yDEly4BJzW3o+gi9X7Qk4Rl5xmgCXWY7aK+cMp8tjw1ZUtpFJKPKb5TVjWbl3IhdP9WcbvWs7zRjByDQBUlzvxSjIApAv8Tdacw460AOBJOWGD6U8HIIPXFRj7ozTyRtJ70AaWi20N0GiZiJB0IqrPC9tO8TA8Hg1v8AhB7WzSS5uAGbHArC1G6+2anLKowuTgUAQdW96U4C4700fK24VMQNnPegCPDbk9TVm5jMe0kdagjXDK27oc4q1eXAuFGFwRQBVGFPrS4+fPam44oXINAExxn2p0aiV1QVCvALVYt8qpkxg9qAH3CLCQi9ahJYHCjmkDlmYt96gHmgAfL4C9aXacgAU3nNSR7l60ADHbwOtbljul8GaojfehvLeUeylZVb9dlYJ+8a3dAzLpPiG3/vWSyqP9pJoz/6CXrmxfwJ9nH/ANKRUdytpYEcTOTVK4l86d9vSrgOyxII6is1MhScV0kki5UD0qQvsX5R1qEykgZHFK3OCOlAAQx5pMlMueMnijcTwelWLGI3M6q3KrQBrabaz3Nm827YoHHvVHT7FJ7pzIoz2NXtZnMVqsMMmwdxUFtG4tlkRse/rQBu6bPdaOcSNvgJ6D0q6z6dK3nEAM3JFc3PNI8Aw+5h2pkCT3jgD5WFAG61w9hdC50eXbIOoqWfxHfXcqtdcuODmsaYTW7hBzIaQySL98fNQBo6jpEOpn7RFIElPOKZpOj2unOZr3Dydgapx3EgYFSQ1OluGLfvWz6UAdBZa/LDdN/BGB8gFK+u3F9OYrtco3TNc55jFdwFIqz3IJDbCn3aAOmsvDE01z5kDIm7kGrGqXtxoqC3Zlkc8ZFcnBqmqJJ5TXOxRwPenTTTykmaQyGgCLxHBbX9o0ip/pA5OK5TTVnkk8mQEY9a7S2u4ljImj/Gs5Y4bm4cxYQetAGbJNNERGpBXuKaXEvO3GKdcJ5M7LnJHemhiRzjFACb88dqjIy2O1OI60inFAD0O3gjjtTScZKjIoJyRTlPzY7UARYLHkUzOD8vWrjFBwehqKWNV+50NAEO4t96l5HvQBxTkPG00ANPP4UxsFT6090xyOlBQMmfSgDKYESGno53c1JcBVPHWolwcE0AXAQy1VlOGwDUqnI4qtMBnk0AIuXkrUTMcQHY1l2eDcVqXLhgBGKAGEAkr2IrQ8PXot7ry5GIQ8Z9Kyznq3WmrlTnt3oA3Nbt4/tBaKQSK3PHasaUKDjvThIQQwzgdajmILBqAKuCAATTwARzTOppelACjkYp4wB70gxnqKVhyORQBMkrJEVB69qb0Xpt+tIp2uGPPpUlw3nbScDFADcAMOeKsSQ4jDZ+WoYUUyAseKluZM/Kv3aAIwMcil3ZOKbyFpQOhoAXHSnFGxkDI7008nbUqSmNDH1BoAjwSygdKtSkJFgY5qGAHfyKbOW34PH1oAQdOKBxQQRx6d6cuO9AAEzzT+e9IGxxThQAhGR0qSF5Y3KxO6F12NtONwPY+o9qZnmrFgubjcwJx0pNX3As3i7LVVPWs5Wx8pHFX9TbJX0FUuMbsYFMBhzuwaGyWGOlCNuYsegp64Ce56CgAVTJMsSDJPWtpDFYR7MfvCKrWqJp1q1zNjzD0FURMzxyXMh5boDQBBeOZrweYSTnitKz3FAm7gdqyI8kmRuta+lAupJ60AX4YVRsnrUiSkP+7G1h3pikb8H9KNuDwRQBJuYtuk5b1oDgt+8HPao/xpGBOCSM0AObGc9B2pBGp5LZpcjFJ9w8d6AHD5BhaByQS2PpSd8U9VAGWoAbMkUkZBPzeopqrtj2hj7UOFPKil3nYARj3oAo3bMIyCaz1maPlTireoPlvlOazmUkEUAXmInTdxuqsAQcUyB9jYOak6PnIzQA8J70hAzjGKQffznkU9mD+zUAQuCDxSFSeQeakxzgnmgDLdaAGrzwwpdwxtPSlZWHbimYGTmgBCMdKACWCngUcjrSsN68dRQA6cMigAfKe9RjaqetWYpWlgMYGcVTiVQWVjg+9AFKbBkJqPcCRn9KmnTBJHSoYsM3NAE2SB04qlcHD5NaLZC8YIqjc7QOetAEunkGTJxir0m0/dqrYRBot2RVsBCMUAQk9qQkjFK33sCjFACgimvz060oAJ96Rz2HX1oArKcqc0uOOabindRQA4Abc5pKP4RSZ5+lAE2fl4oXnrxSlwU2gYP86VVwuWoABjp096AeetJkZ56UuPSgB5POaUANjPFMIOaeoGBQAEbHpG55pS2X56UpAMoGcAigC1pirJP85+X17U7U7ciYMmWT1FSeHTbpfmG7P7lu9W9WuEgumgt4i1u3RzQBjuAD8vTvQvShR87Z+7TsDtQAINxzTmPOMYxTQQPrS8sOaAHIcnHpVuyJEvtVRcCpIXYP7UASXjbpxzkVA4y20dKkmA3E55poHy8GgCNlxxjj1qfTbcTTb3yETmofmY7fWr9wwsrEKPvtQBT1e5N5dCJP9WtVrpiwSJeF70tsCA0jfeNOAySW60AMwANtbGlgBQPWsgjqa2NJwUOe1AF7YEkOTxRuXNN58wg0owD0oAR8LwATmgDg0rHJ4oIymT1oAjjzzmpFXPJqMHJwRUvbAoAUAAZ60mSTQE96cV44PNACbR9ahu3CJip8AL15rO1Bx0JoAzpmYykrTCcPg04n5sihlywJoATA35NPYfOOKbIQMe1SZ8wAjtQAij5qkCDO5qjTJenPkfSgBGxu46U3I380oG7NNH3sGgCVnzxkVCylqcFG7I60pBP3aAEI9aTgKSKULgc800tg8dD1oAt2QEcTS8dO9Z0uHd5OhzT7iRwgVPu1Ew/dcnmgCk0jEsDRAhZqbMecDrVi1+UDigCQIUU5NZdwQ8hB61rTA+WSRWNKf3maANHTMY25qZsCQgAgVX0sfvKuzgCSgCNhyMmh+2KU4NBxwKAIucUSHpTjjNNkzkY6UAVyOOKE6c9aB0zmkQgkk8UAL8x6U7AYDNEZKk+9TWMPmzEZwPWgBoAxjNPzldpOaS4QR3Gwc46mkPsOaADGOvNSRYxzTM5GO9BOcdqAHsQTx0pVAyKaoH4U7uB2oAfGqu+KJVHmKB2oUhW4pGOXzigBz4SZAOme1dBf38T6WkUcQDAYLY5rnsnqcZrShYTwbOM0AZ6nCY6+9KMnpRKjROUanRfLzQAFcHNKTxSfeNOA4x2oAapx1p6HnimHin9EzQA5ly1K4VE5xntTEbcRmphEkjDfQBLYQjmSToOlVr6U3EvPReBVy4dY7cInFZxJJz2oAI+eKe2NvvSqo2570yQUAR859q2dM2hR2rHJHatnTV/d896ANCZUOGjNVb0yR2xljBJFXSqqvyUqjcNpGQe1AHMWOrPJNtmG3nvW0X8xMhulZniKxjgAlQYb2qpp0kvllnOFFAG2j78noBUZ1CPO1cZFVklLxkJxmsw2FzPcFYQcnqaAN+0m+1viB846irR++VxyOtV9J0p9OjLF8ueoq7GBlm7+9AEcsYEeScGsO7fe+CM+9a1y+FbOaxmYbzQA1VAGaCDnrSdH5PFOP3c0ANYALyM0+I8ccCm545FSRe1AARt6d6UklcYpf4qXYx70ARqME0bBnOKcRzg05iNmB1oAjKdwaVWCfWmjOCT+VIPmNAAc9qY+CuAcGpRkggCoyBxnrQBMiRiA+YRu7VQlwqkA59KsXAI25HFVrr7vTFAGc7bWyeua0rQHYCwrOcbnA7ita2BKgY7UANuSDEawJf8AWn0rfu02J7EVgzcyH0oA1NPT5Qw4qxNhjmq+n58nAqcjIxQA08KTQFyMmlCnFIAPfigBjAZ60sigKDmkPLUsgBwO1AFYjC80iqCOaHI6igfL1oAFyQ1aulWhNlJOTjbWWTjA7sa3ZGNlpG3s4oAx2fzMseuetGeBimRqNuR3pc/MPSgCRR3HWgj1pccZFIKAHqMrxSpz0601Tt+hqRB+8GKAEXPmbT1pXUq3SpbdQ1wc0Tj99jsKAIGzuAJwKliR0kBBwvrUMi+ZJnOMVoLDJewCKIYK96AI7r5ivOfeol9B1qVo/JXyycsvWobcHcWNADwCOKUkY4oO52JFEY7tQADn60N93FGDvJFDZz7UAKvA96niJxzVcdalRyuaACdieOtJj5QCKT5mfPal3lmwKABcgYpkh7Gpdp34pk4w1AEITBrb0w8AN0rHwSK2NNUbQTQBonCtjPFPHysMdajY88/d705n4BXtQBB4ijhFiJm5f+7XO2ZDrlvlB6CtzU2ElszE5I7Vy0MytMQGwQelAGze27Jbr5fygnrW3pVs1rYCTO4n+KuUlvXLKjt8ma6zSrkC0CMcxYoAkzuAYZ560yRgWVV60sk6/djpq4GS33jQBU1RlEe0Y3Vj4Bxmr182WOTVP5cgd6AGsoLY7UsiYHyilUbpcVNO3HAoAq+2OakTgjIxTTnINSAksMigBWHzcU4HtnmmSKS2RSocDB60ADDOcdajx1J61M0g6d6YV3D5aAIyTmmr8rc04jBwetBGWFAD4P8AXAN0NXWs1juUc8pWfFkzgFsYqTVLuSLAiOc96AH6wyNcIseMCsi/bYOOSKsxMz8zfeqheHEvNAEEP7yXPQ1uWa1j26kSbgOK3bIDZuHWgCtfkNGR6Vzsg+fFdFqgIjJrmzkufrQBs2QCw/LUuKLNQLcZp5GBQBGQ275e9TXFrJHbiRuhqLcU5FLPLM8Y8x8qOlAELLhFb1prZ61K6nyQc8VG5+THegCpgE8UrnIApFUjJocZPy0AWLKPfqEKN0zWz4rmQeRBH+NZOnnZcCT+70qTUX+0XG8ckUAVifnwOmKdGpySOtRscygE496u4jjQFWyaAInHT1pozvppYs+alVGHzHpQAoAzg1PEEyBULcncKZn5hjrQBdiULNlahn+aY5p1nLiXD0XIAkJWgCKLiYgdMYrS0W4a3nKYznvVOBMuPWpoQVvV7ZNAC6kuLpmJ+92qsMjkVqa/FsCOPSqEa7o93agBsTbW+tSmM/fU8VER2zxTg5HQ0AJ1PvTyABzSKAxz3psgJPNABwfpSjpQucY7UYI6UAIVJ6UgDA8VIo9TSY+Y4oAkhDN1pkqDeamtxz71FNxIRQBEEPY8VsaaCY+e1ZJyBx0rS04kLgUAaSg5I7Un3c4o3Fc0xmwOKAILwqtu+4dq4K8YG4PlZBzXd3zBrV88kCuDuT++bA4zQBJYBprxVfkZru4o/KjQAdq47w8MXYbGea7YyGQgBcYoAk+VUBA5oZztLkUgIPAHIpJ3/dkUAZVxJvlJqueWxipTw59KYDl89qAHQJmTNPnHz1JajCk4qORtz0AREE5FOiG360gYgkd6kReM+tACuC44pFXAINTAbRTH+6T3oAgK805aBnFAXBz3oAZLkHpTQuetSsMrzUfOCaAGOuTgU4R+dx0x3oVcEYPJq4luWgLDg+tAFJgASOw71iXb7pmA6CtqY4ibPasGY5JweaALengs9bsEeYzxyKx9IiYtW+3mIgAXIoAyNVYiAhq55Tl1+tbmtNiPB4rDi/1wB6ZoA6GL/ULQyjbSqMRqB0ob7ooAjcZIFNfpint94Y60Nw/JxQARjKYxUJAJKmrFs2CSaif/AFhOOKAKWDnrxSKKCacuMZzQBPDgIeaYjZziliHyGo4uNxHNADJQcg5+tSrjaMDFJKmUz3pY/wDV8igBUwavsT9l3Yqku0Kc1f4Fj1oAq8lM/pUZ+WQcU9SGUHNJIeRigAmLK6sKtAiSIY6ioWG8AYp8SlRigCS2O2cZNT3gIkRgRx3qoTtfcDzUsjmRBz0oA2rjF1ZKMZYCqNtFiB0PWp9MmHlFT+dIBmchTn2FAGWq8kE4NIRx1qzNGElIPFV2XJIoAajENxUzHio0XBqUDI5oAQDIzQDjggmlHXApTQA3sTRGMGnEZFA9BQBJbgh8GmSDM3NTQIWBIPNV3yJstxQAsgGKvWHABqk+Dmrlgc8UAacgG0HsajOGXgVIqmQbT3qIEoxUigCu67o2HqK4fUInjuZF6AHNd+sZPINcZr5xeFemTQBd8LWx3ecRkeldOzEyHAqpokAisFK8kirSow5NAEoUbcjrVe7JC9KsK2Tgc1S1CQgbcUAUj3J5oUDaTTgvy+9AHy4NAFzTk3xkkcVVuwElwozWhZ/u7Y8c1QkOXO7rQBCFBOasggoABzURTFSLlVyBmgBATzmhhx1GKd94VGwwOaADikIz0pMUCgBPamEdsVL05pH65FADFTMgAqxNIygRrwvem2y8E96jcl5Ce1AFe+ZfJKjjArnVGZDz3ra1MjacVjoMMO57igDe0VQjAsOPWtyWbCgKM1k6XETGrHpWkcbeBzQBzevuS+Ky7NA84zV3W2P2gg81W0/m4HFAG3LHhVxSNyMVMMNgE1E42tx0oAIkLzKMUt5GquAetOgy1wiKcMxq5r9stuE2ncx9KAMwKQo20xgT061YVSSBntUJRllPr6UAZwGc0/b8lIMBcDrT3IC7VoAUHbF9ajTO2nPllGKVRQBbSIGDdnJFQkFxjbgetOikKsABn2p94xAU4wO4FAEGMcYzUzZ8raDkU3YVQFuAaaDQAYAxiiThhSj71Nk60ASoCcYzirPCD1JqpE/apScYzQArDvSg4X2pS2RTXGFNAFmCQRJuB49K0tLtZLmOS4BwBWM4xCvvXWaJFs0sknANAHO3WTPyKhwS2QK07+MklVUfWqCqwHSgBmDnkUopxz3FRs3PFAD+nNHWkLdKkVe9ADXGF4oUfIW9Ke/Ix2oA2pt65oA0NJs/tMZlVsEdqz73i5K45rW0xxa25IJyayLpWa8Mh6UANUEryOavaf8AexiqyksCQKs2DESYoA1CNrA5/CmyKG5704rnk0hULzmgBifIpJriNRxNqvznjNdy+Gt2J9K4G8ITVCT60Ad7aRolkgX0pQDj5s02wIezRl64pW3SDCUAOVFUFs1l3zb5MY49a0pcCEr3rN2EnDUARBDgEHNDDI96lYbVPbNRt93HegDb0y3M1q5boO9Y84AuWQDNdJZsIdHfPBIrl4h+/djz9aAJJI8AHNORSy8VHICasW5wuKAIsHt2prgntU0qmM8d6Y3TIoAjCjHvSFfUU7GAT3qa3cFhuGRQBCqErgA5pbiHbHnoa05BHGuVFQRwm8uEHIWgAjtvL0/zG6ms1F6t611uv2og02ONMZ74rmGQRw0AYWqSYyPeqFqN0oqfVXLSED1pLBQ0qr3oA6fTE/dgY4q1MB82Owp1ioiiGfSm3ZHkuw4oA4rViTctznFO0OMyTEntUN6czOfetTw7B8jPQBekABIHWkVQyHHJFEh/ekU0ExDPr2oAjgc+cG6MKluZXmf5zk1EgG8HualmUDkdTQAyH/X89qS5GJiQadF8pJNRsd5NACaaITZymYfvMcVnxk/PkYOadE5U0pGSSeKAGxdCDTo/vEn7tNQcE05RhST3oA0NJiSSRpG+6tQXL+dct/dB6VPaSGOzKjjNUkGN3qaAJJ3LYXsKYop8Shgd1Jt546UAIgyeaST71SIMGmTCgBqHmps569aqKSW4q2mNuSeaAHrk9RStyuOcU+HCklqeWDZGKAGSgmGPbyBXVQyINGGGww7VyyDKewqxbXLG3aMk0AXp5N0GeCaqbvlzxTF3bTk01c7aAHD5gTUWBnjpUq5CkU3GM4oAaBnt0qSMEtwOO9JjYOnJq3BF5cPmN3oAgkXI47UkwAVfarhQPFv7VTbAUnrQBqpDv08SLkNWV13FjyK1bOTdp5UZrJXJZgaAHR8A4qe0P72o1GAcdKktiBKM0Aax5AJpjYHJqSQ/ICtQF94PB/KgB0kZktnZTjAzXA3Q36hhf72DXeMX8tucKRXCzLs1cHsGzQB2tkhjtUCk5xVoYiTOeTUccga1QoO3WmKvALHPNAEs+PJyfvVQQFiTVi8mwuKroQVyDzQBHKG3D0peDKqLzyKUHLYan2QX7VnsKANfVXEGnKuSCw6VgIMJnuavavcG4lRByBVRhgAYoAcFyopUO1h6VIgyBgUOBjA60AT3AUw7hycVSHI4qdWOAG6UhQMcCgCNYjIMCn28DCUAdM81atFCdasJtBLDGaAEulD7I0H1qxMI7GFGXr71SFwd5IHSo7yU3MW3OaAL8t8L613N2rBuHGxuelPidoozH0qtckLbtmgDmrt99wx9Ku6IhkuM46Gs2RsztXR6DFtUNjrQB0KIPLA71S1b93aN6VpIuQpUVmeK5AljtH3iKAOImYOxI9a39EXy7Yn1rnW5UY6k10tihWzWgCSQEtu70SKCvPWnrjbzVuGGM25ZiM0AZwUAj1pWUk+1OUAs3rUpOI8kUAVzgVEpGCR1p7jKk/lTEUeWfWgCitPFFFACL9ylH3DRRQBcg/496rnqaKKAHxfeFPPUUUUAL/H+FRXHSiigCvH941YXoKKKALQ6U5OpoooAdH9x6bZ/xfWiigC0v3aBRRQAlIvWiigB7/eFXLr/AI9F+goooAen/HhWef8AVtRRQBqab/x5n6Vnf8tH+tFFADh3p0H+sNFFAG4P9R+FRL0NFFADJP8AUH6VwF//AMhA/wC9RRQB3Vh/yDU+lSW/Q0UUAU77tTIv9XRRQA5KdZf65qKKAIJf+P2pJPvCiigCWLt9KQ/eNFFACjoafF96iigCwvSlT+KiigCsvV6Sx/1jUUUAQ3X+uNUb7/j3NFFAHKN/rj9a7DRP+PYUUUAdJadBXPeNP9VRRQBxQ/h+tdba/wDHov0oooAP4TU8f+ooooArJ/rGqaf/AFIoooAqTf6oUyP7lFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal STIR MRI of the pelvis shows multiple low signal, intraarticular loose bodies in the right hip joint, consistent with synovial chondromatosis (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cecilia M Jude, MD, and Shahla Modarresi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7922=[""].join("\n");
var outline_f7_47_7922=null;
var title_f7_47_7923="Patient information: Separated shoulder (The Basics)";
var content_f7_47_7923=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16323\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12895\">",
"         Pendulum stretch exercise",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/26/22946\">",
"         Patient information: Frozen shoulder (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/21/20818\">",
"         Patient information: Acromioclavicular joint injury (shoulder separation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/21/37201\">",
"         Patient information: Frozen shoulder (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Separated shoulder (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/separated-shoulder-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H32441578\">",
"      <span class=\"h1\">",
"       What is a separated shoulder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A separated shoulder is a condition that causes shoulder pain and swelling. It happens when certain ligaments in the shoulder joint tear or get stretched too much. Ligaments are strong bands of tissue that connect bones to other bones. The shoulder joint is made up of 3 bones: the collar bone, the shoulder blade, and the upper arm bone.",
"     </p>",
"     <p>",
"      The most common causes of a separated shoulder are falling on the shoulder or getting hit in the shoulder.",
"     </p>",
"     <p>",
"      A separated shoulder can be mild or severe, depending on how many ligaments are torn.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32441585\">",
"      <span class=\"h1\">",
"       What are the symptoms of a separated shoulder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can be mild or severe and usually include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Shoulder pain",
"       </li>",
"       <li>",
"        Swelling in the shoulder",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32441592\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might. Your doctor or nurse will talk with you and do an exam. He or she will also probably do X-rays of your shoulder.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32441599\">",
"      <span class=\"h1\">",
"       How is a separated shoulder treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most separated shoulders heal on their own, but they can take weeks to months to heal completely. To help your shoulder heal, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest the shoulder &mdash; Avoid lifting things, reaching overhead or across your chest, or sleeping on that shoulder.",
"       </li>",
"       <li>",
"        Use an arm sling to protect your shoulder and keep it still",
"       </li>",
"       <li>",
"        Ice your shoulder &mdash; Put a cold gel pack, bag of ice, or bag of frozen vegetables on the injured area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin. Use the ice (or other cold object) for at least 6 hours after your injury. Some people find it helpful to ice longer, even up to 2 days after their injury.",
"       </li>",
"       <li>",
"        Take a pain-relieving medicine &mdash; Ask your doctor or nurse about taking an over-the-counter medicine for your pain, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;),",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;), or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have a severe separated shoulder, you might need surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32441606\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Different exercises can help your shoulder get better.",
"     </p>",
"     <p>",
"      To keep your shoulder from getting too stiff, you can do an exercise called the pendulum stretch. To do this exercise, let your arm relax and hang down while you sit or stand. Move your arm back and forth, then side to side, and then around in small circles (",
"      <a class=\"graphic graphic_figure graphicRef50148 \" href=\"UTD.htm?12/37/12895\">",
"       figure 1",
"      </a>",
"      ). Try to do this exercise for 5 minutes, 1 or 2 times a day.",
"     </p>",
"     <p>",
"      Other exercises can help strengthen the muscles around your shoulder. Your doctor, nurse, or physical therapist (exercise expert) can show you how to do these types of exercises. He or she will tell you when to start them and how often to do them.",
"     </p>",
"     <p>",
"      When you do shoulder exercises, it&rsquo;s important to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Warm up your shoulder first by taking a hot shower or bath, or putting a heating pad on it.",
"       </li>",
"       <li>",
"        Start slowly and make the exercises harder over time. For example, when you do the pendulum stretch, keep the circles you make with your arm small at first. Over time, make this exercise harder by making bigger circles or holding weights in your hand.",
"       </li>",
"       <li>",
"        Know that some soreness is normal. If you have sharp or tearing pain, stop what you&rsquo;re doing and let your doctor or nurse know.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32441613\">",
"      <span class=\"h1\">",
"       When will I be able to do my usual activities again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on how severe your separated shoulder is. If your injury is mild, you might be able to return to your usual activities after a few days. If your injury is more serious, it might take weeks to months.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32441620\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/26/22946?source=see_link\">",
"       Patient information: Frozen shoulder (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/21/20818?source=see_link\">",
"       Patient information: Acromioclavicular joint injury (shoulder separation) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/21/37201?source=see_link\">",
"       Patient information: Frozen shoulder (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/47/7923?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16323 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7923=[""].join("\n");
var outline_f7_47_7923=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32441578\">",
"      What is a separated shoulder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32441585\">",
"      What are the symptoms of a separated shoulder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32441592\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32441599\">",
"      How is a separated shoulder treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32441606\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32441613\">",
"      When will I be able to do my usual activities again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32441620\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16323\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/37/12895\">",
"      Pendulum stretch exercise",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/21/20818?source=related_link\">",
"      Patient information: Acromioclavicular joint injury (shoulder separation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/21/37201?source=related_link\">",
"      Patient information: Frozen shoulder (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/26/22946?source=related_link\">",
"      Patient information: Frozen shoulder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_47_7924="EB nevi 2";
var content_f7_47_7924=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa nevi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Epidermolysis bullosa nevus typically tracing the outline of a preexisting blister.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7924=[""].join("\n");
var outline_f7_47_7924=null;
var title_f7_47_7925="Lorcaserin: Patient drug information";
var content_f7_47_7925=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lorcaserin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/59/30646?source=see_link\">",
"     see \"Lorcaserin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F16052200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15673835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691381",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you lose weight.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15673834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4044982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lorcaserin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15673839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have sickle cell disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15673840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15673841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe or slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3546452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Erection that lasts more than 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15673837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F15673838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F15673842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15673843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87345 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-189.41.172.26-304210EFA6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7925=[""].join("\n");
var outline_f7_47_7925=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16052200\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673835\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673834\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673839\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673840\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673841\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673837\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673838\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673842\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673843\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/59/30646?source=related_link\">",
"      Lorcaserin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_47_7926="EP study tracings bidirectional isthmus block";
var content_f7_47_7926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60090&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Intracardiac and surface ECG recordings during electrophysiologic study and radiofrequency catheter ablation of atrial flutter showing bidirectional isthmus block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high right atrium (HRA), eight recordings from a catheter extending from the lateral right atrial wall through the tricuspid valve-inferior vena cava (TV-IVC) isthmus and into the ostium of the coronary sinus (CS15-1 through CS1-2), and right ventricular apex (RVA3-4) in a patient who has undergone ablation for atrial flutter. Left panel shows pacing (PA) from the lateral right atrial wall; the impulse is propagated down the lateral wall of the high right atrium, generating an atrial electrogram (A), to the lateral TV-IVC isthmus region (CS13-1, CS 11-1, CS9-10) where conduction is blocked. The medial aspect of the isthmus is not depolarized until a wavefront of activation comes down the interatrial septum or from the low left atrium; the distal poles of the catheter are therefore depolarized late and in the opposite direction, from the coronary sinus ostium back towards the medial TV-IVC isthmus (CS 3-4, CS 5-6, CS 7-8). Right panel shows pacing from the coronary sinus ostium. In this case, the medial isthmus is depolarized promptly (CS 3-4, CS 5-6), but conduction is blocked within the isthmus (CS7-8). Thus, activation of the lateral wall of the right atrium is delayed until a wavefront travels up the septum and across the roof of the right atrium. Activation of the proximal poles of the catheter is therefore delayed and occurs from high to low (CS 15-1, CS 13-1, CS 11-1, CS9-10). Patients with bidirectional block across the TC-IVC isthmus have a low rate of atrial flutter recurrence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7926=[""].join("\n");
var outline_f7_47_7926=null;
var title_f7_47_7927="Substernal goiter CT I";
var content_f7_47_7927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51935%7EENDO%2F63758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51935%7EENDO%2F63758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Substernal goiter: Appearance on CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan showing large obstructive goiter at level of clavicular heads with concentric narrowing of the tracheal lumen and displacement of the esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas S Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Substernal goiter: Appearance on CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan showing substernal goiter in the anterior mediastinum at the level of the aortic arch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas S Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7927=[""].join("\n");
var outline_f7_47_7927=null;
var title_f7_47_7928="Clinical features and diagnosis of bacterial meningitis in the neonate";
var content_f7_47_7928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of bacterial meningitis in the neonate",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/47/7928/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/47/7928/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/47/7928/contributors\">",
"     Carol J Baker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/47/7928/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/47/7928/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/47/7928/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/47/7928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/47/7928/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/47/7928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial meningitis is more common in the first month than at any other time of life [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite advances in infant intensive care, neonatal meningitis remains a devastating disease.",
"   </p>",
"   <p>",
"    The mortality rate declined from almost 50 percent in the 1970s to contemporary rates of 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. However, during the same time period, the morbidity rate was relatively unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/6\">",
"     6",
"    </a>",
"    ]. Survivors remain at high risk for neurologic sequelae and lifelong impairment as a result of infectious insult to their developing brains [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, etiology, clinical features, and diagnosis of bacterial meningitis in the neonate will be discussed. The treatment, prognosis, and complications of neonatal bacterial meningitis are discussed separately, as is bacterial meningitis in older children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=see_link\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The documented incidence of bacterial meningitis in neonates (infants &lt;1 month) has remained remarkably stable since the 1970s, despite changes in the neonatal population and in neonatal intensive care units [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/8\">",
"     8",
"    </a>",
"    ]. Depending upon the inclusion criteria, the incidence is between 0.25 and 0.32 per 1000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Although specific data to document this are lacking, it is our impression that bacterial meningitis in the neonate is encountered rarely in clinical practice.",
"   </p>",
"   <p>",
"    Bacterial meningitis occurs in as many as 15 percent of neonates with bacteremia. Among infants with invasive group B streptococcal (GBS) disease, 5 to 10 percent with early-onset and approximately 25 percent of those with late-onset infections have meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Risk factors for neonatal sepsis and meningitis include low birth weight (LBW, &lt;2500 g), preterm birth (&lt;37 weeks' gestation) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], premature rupture of membranes (ie, before the onset of labor or regular uterine contractions) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/16\">",
"     16",
"    </a>",
"    ], septic or traumatic delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], fetal hypoxia, maternal peripartum infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/17\">",
"     17",
"    </a>",
"    ], galactosemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], and urinary tract abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early-onset infections, acquired in the first three to six days after birth, and especially those in the first two days after birth, reflect vertical transmission from maternal genital tract flora [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/21\">",
"     21",
"    </a>",
"    ]. Late-onset infections, acquired after the first week of life, suggest nosocomial or community acquisition, although the maternal flora now colonizing the neonate may still be a source of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In developed countries, group B streptococcus (GBS),",
"    <em>",
"     Escherichia coli",
"    </em>",
"    , and other gram-negative bacilli are the most common organisms causing neonatal meningitis; when",
"    <em>",
"     E. coli",
"    </em>",
"    occurs after six days of age, galactosemia should be excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/5,8,23-25\">",
"     5,8,23-25",
"    </a>",
"    ]. In prospective surveillance of nearly 400,000 neonates in the United States (2006-2009), 72 percent of those who had sepsis or meningitis within 72 hours of birth had infection caused by GBS and",
"    <em>",
"     E. coli",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=see_link\">",
"     \"Clinical features and diagnosis of galactosemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link&amp;anchor=H7#H7\">",
"     \"Group B streptococcal infection in neonates and young infants\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In surveys that include infants without regard to gestational age, gram-positive organisms other than GBS (including",
"    <em>",
"     Enterococcus",
"    </em>",
"    , coagulase-negative staphylococci,",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    ,",
"    <em>",
"     Listeria monocytogenes",
"    </em>",
"    , and alpha-hemolytic streptococci) contribute to the total disease burden. However, none of these organisms accounts for more than 4 percent of cases overall [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/26\">",
"     26",
"    </a>",
"    ]. These latter gram-positive organisms constitute a greater portion of the disease burden among very-low-birth-weight (VLBW) infants (birth weight &lt;1500 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <em>",
"     Neisseria meningitidis",
"    </em>",
"    also rarely can cause meningitis in newborn infants. Among 22 cases of invasive meningococcal disease identified in neonates between 1990 and 1999 in the Centers for Disease Control and Prevention Active Bacterial Core Surveillance program,",
"    <em>",
"     N. meningitidis",
"    </em>",
"    was isolated from cerebrospinal fluid in 16 (73 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pasteurella multocida should be considered in the differential diagnosis, especially if contact, even nontraumatic, with companion animals such as dogs and cats is documented [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13321?source=see_link&amp;anchor=H3#H3\">",
"     \"Pasteurella infections\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the developing world, the microbiology of bacterial meningitis in neonates varies geographically [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of neonatal meningitis typically is indistinguishable from that of neonatal sepsis without meningitis. The most commonly reported clinical signs are temperature instability, irritability or lethargy, and poor feeding or vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Temperature instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temperature instability is the most common finding. Temperature instability encompasses fever (rectal temperature &gt;38&ordm;C) or hypothermia (rectal temperature &lt;36&ordm;C). Term infants are more likely to have fever, whereas preterm infants are more likely to have hypothermia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/32\">",
"     32",
"    </a>",
"    ]. Temperature instability is present in approximately 60 percent of neonates with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/31,33\">",
"     31,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic signs of neonatal meningitis may include irritability, lethargy, poor tone, tremors or twitching, and seizures. Irritability is common, present in up to 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/31\">",
"     31",
"    </a>",
"    ]. Seizures have been reported as a presenting feature in 20 to 50 percent of infants with neonatal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/22\">",
"     22",
"    </a>",
"    ]. Seizures more often are an initial manifestation of meningitis resulting from gram-negative than from gram-positive pathogens and usually are focal, rather than generalized [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings of a full, but not bulging, fontanelle and of normal neck flexion are the rule, rather than the exception, at the time of initial presentation of neonatal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. Bulging fontanelle is present in approximately 25 percent of patients, and nuchal rigidity in approximately 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/31,33\">",
"     31,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other findings of neonatal bacterial meningitis and their approximate frequencies are listed below [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor",
"      <span class=\"nowrap\">",
"       feeding/vomiting:",
"      </span>",
"      50 percent",
"     </li>",
"     <li>",
"      Respiratory distress (tachypnea, grunting, flaring of the nasal alae, retractions, decreased breath sounds): 33 to 50 percent",
"     </li>",
"     <li>",
"      Apnea: 10 to 30 percent",
"     </li>",
"     <li>",
"      Diarrhea: 20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory features that are characteristic of neonatal bacterial meningitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolation of a bacterial pathogen from the cerebrospinal fluid (CSF) by culture",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      visualization by Gram stain",
"     </li>",
"     <li>",
"      Increased CSF white blood cell (WBC) count (typically &gt;1000",
"      <span class=\"nowrap\">",
"       WBC/microL,",
"      </span>",
"      but may be lower, especially with gram-positive organisms) with a predominance of neutrophils",
"     </li>",
"     <li>",
"      Elevated CSF protein concentration (&gt;150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in preterm and &gt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in term infants)",
"     </li>",
"     <li>",
"      Decreased CSF glucose concentration (&lt;20",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.1",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      in preterm and &lt;30",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.7",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      in term infants)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Blood cultures often are positive for the same organism as the CSF culture but can be negative in as many as 30 or 38 percent if CSF cultures are matched to a blood culture within three days of the lumbar puncture (LP) of newborns with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/9,27,34,35\">",
"     9,27,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of neonates with suspected sepsis or meningitis should include a review of the prenatal history, delivery, and complete physical examination. Because the clinical presentation of bacterial meningitis in the neonate is nonspecific, neonates with suspected bacterial meningitis should undergo a full laboratory evaluation for sepsis. This includes a complete blood count with differential, blood culture, urine culture (if &gt;6 days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/33\">",
"     33",
"    </a>",
"    ]), and lumbar puncture (LP) (for cerebrospinal fluid [CSF] cell count, protein, glucose, Gram stain, and culture). Examination of the CSF is necessary to establish the diagnosis of bacterial meningitis. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;When signs of sepsis are present, an LP should be performed, ideally before antibiotic therapy is initiated. When clinical instability precludes performing an LP at the time of the initial diagnostic evaluation, antimicrobials should be provided in doses sufficient for the treatment of meningitis until such time that the infant's condition permits evaluation of the CSF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Empirical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Interpretation of CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of CSF studies in newborns can be challenging. The range of normal values for CSF parameters is different for neonates than for older infants and children, and also varies according to gestational age, chronologic age, and birth weight (",
"    <a class=\"graphic graphic_table graphicRef54464 \" href=\"UTD.htm?35/19/36158\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/35-38\">",
"     35-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, there is considerable overlap between CSF parameters in neonates with and without bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/33\">",
"     33",
"    </a>",
"    ]. CSF white blood cell (WBC) counts exceeding 21",
"    <span class=\"nowrap\">",
"     cells/cu",
"    </span>",
"    mm",
"    <sup>",
"     3",
"    </sup>",
"    have a sensitivity and specificity of approximately 80 percent to predict culture-proven meningitis, but neonatal meningitis occasionally can occur with normal CSF parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/34\">",
"     34",
"    </a>",
"    ]. Additional features that assist in arriving at a provisional diagnosis include the clinical status of the infant, other laboratory parameters, and the clinical progress. For infants in whom the initial CSF is obtained so early in the course that CSF findings of bacterial meningitis are not definitive, the repeat lumbar puncture 24 to 48 hours later will provide resolution. When the meninges are inflamed, the second lumbar puncture always shows a pleocytosis, and other parameters are consistent with the diagnosis of meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cell count",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the neonate, a CSF WBC cell count of &gt;20 to 30",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    is consistent with meningeal inflammation, and bacterial meningitis should be a consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/26,34,37,39-41\">",
"     26,34,37,39-41",
"    </a>",
"    ]. A median CSF WBC count of 271",
"    <span class=\"nowrap\">",
"     cells/mm&sup3;",
"    </span>",
"    has been noted for infants with group B streptococcal meningitis in the era of intrapartum antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/42\">",
"     42",
"    </a>",
"    ]. The CSF WBC is typically greater in neonates with gram-negative meningitis than with meningitis caused by gram-positive organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the neonate, a CSF protein of &gt;150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in preterm and &gt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in term infants is consistent with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/40,43\">",
"     40,43",
"    </a>",
"    ], but CSF protein values are highly variable in neonates both with and without meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/34,37,38\">",
"     34,37,38",
"    </a>",
"    ]. The median CSF protein concentration was 68",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (95",
"    <sup>",
"     th",
"    </sup>",
"    percentile value 115",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    for a group of ~140 term and near-term infants &le;28 days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Causes of elevated CSF protein that should be considered in the neonate without CSF pleocytosis include parameningeal infections (eg, brain abscess), congenital infections, and intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=see_link\">",
"     \"Overview of TORCH infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=see_link\">",
"     \"Management and complications of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;A CSF glucose concentration &lt;30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in a term infant or &lt;20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in a preterm infant is consistent with bacterial meningitis in the neonate, but CSF glucose values are highly variable in infants both with and without meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The ratio of CSF to serum glucose is not useful in acutely ill neonates (their serum glucose may be increased secondary to stress or administration of intravenous glucose before the time of evaluation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Gram stain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of an organism on CSF Gram stain can suggest the diagnosis of bacterial meningitis and has the advantage of providing a presumptive etiologic diagnosis before culture results are available. However, the absence of organisms on Gram stain does not exclude the diagnosis. Approximately 20 percent of neonates with culture-confirmed bacterial meningitis have negative Gram-stained smears, especially those whose illness is caused by",
"    <em>",
"     L. monocytogenes",
"    </em>",
"    . Neonates with culture-proven meningitis can have negative Gram-stained smears if the concentration of organisms in the CSF is low [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\", section on 'CSF analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Traumatic LP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjustment of CSF WBC in the setting of a traumatic lumbar puncture does not improve diagnostic utility and can result in loss of sensitivity with only a marginal gain in specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/47\">",
"     47",
"    </a>",
"    ]. Neonates in whom the lumbar puncture is traumatic should be treated presumptively for meningitis, pending results of CSF culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal meningitis should be suspected in any infant younger than one month of age who presents with clinical findings of sepsis or meningitis and in neonates who have positive blood cultures. The clinical findings can be subtle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    limited to isolated fever or hypothermia. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Isolation of a bacterial pathogen from the cerebrospinal fluid (CSF) culture confirms the diagnosis of bacterial meningitis. Pending culture results, neonates who have undergone evaluation for sepsis and meningitis should be hospitalized and treated with antibiotics for presumed sepsis and meningitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Empirical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CSF culture may be negative in neonates whose lumbar puncture (LP) was delayed until after antibiotic administration. In such infants, increased CSF cell count and protein concentration usually are sufficient to establish the diagnosis of bacterial meningitis.",
"   </p>",
"   <p>",
"    The administration of intrapartum antibiotic prophylaxis (IAP) prevents approximately 80 percent of cases of early-onset group B streptococcal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/48\">",
"     48",
"    </a>",
"    ]. If the infant is infected and the bacterial pathogen is susceptible to the antimicrobial agent that the mother received, the blood culture in the infant may be sterile despite a clinical course that suggests neonatal sepsis. Such infants usually have undergone an LP (clinical status permitting), and, if so, increased CSF cell count and protein concentration can be used to establish the diagnosis of meningitis if the CSF culture is sterile. The administration of IAP has not resulted in \"missed\" sepsis in healthy-appearing infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2552?source=see_link&amp;anchor=H2901877#H2901877\">",
"     \"Management of the infant whose mother has received group B streptococcal chemoprophylaxis\", section on 'Overview of management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If blood and cerebrospinal fluid cultures are negative for bacterial pathogens in the infant with suspected meningitis based on clinical or laboratory data, the differential diagnosis of aseptic meningitis should be reviewed, particularly with the aim of identifying treatable entities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7928/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial infections &ndash; Partially treated bacterial meningitis, bacterial infection with a parameningeal focus (brain or epidural abscess), tuberculosis",
"     </li>",
"     <li>",
"      Viral infections &ndash; Herpes simplex meningoencephalitis, congenital cytomegalovirus, enteroviruses, rubella, lymphocytic choriomeningitis, congenital varicella",
"     </li>",
"     <li>",
"      Spirochetal infections &ndash; Syphilis, Lyme disease",
"     </li>",
"     <li>",
"      Parasitic infections &mdash; Toxoplasmosis, Chagas disease",
"     </li>",
"     <li>",
"      <em>",
"       Mycoplasma",
"      </em>",
"      infections &ndash;",
"      <em>",
"       M. hominis",
"      </em>",
"      infection,",
"      <em>",
"       Ureaplasma urealyticum",
"      </em>",
"      infection",
"     </li>",
"     <li>",
"      Fungal infection &ndash; Candidiasis, coccidioidomycosis, cryptococcal",
"     </li>",
"     <li>",
"      Trauma &ndash; Subarachnoid hemorrhage, traumatic lumbar puncture",
"     </li>",
"     <li>",
"      Malignancy &ndash; Teratoma, medulloblastoma, choroid plexus papilloma and carcinoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional evaluation that may be helpful in distinguishing among the differential diagnostic possibilities includes review of the prenatal and perinatal history, with particular attention to maternal illness and contacts, animal exposures, and travel; examination of the infant for focal signs of disease (eg, ophthalmologic examination); and radiographic examination of the long bones, skull, and brain. Definitive diagnosis may require culture, antigen detection, polymerase chain reaction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serology. Treatment for some of these conditions may be warranted, pending definitive results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=see_link\">",
"     \"Overview of TORCH infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial meningitis is more common in the first month than at any other time of life. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for neonatal sepsis and meningitis include birth weight &lt;2500 g, gestation &lt;37 weeks, rupture of membranes before the onset of labor, septic or traumatic delivery, fetal hypoxia, maternal peripartum infection, and galactosemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Group B streptococcus and",
"      <em>",
"       Escherichia coli",
"      </em>",
"      are the most common bacteria causing neonatal meningitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonatal meningitis should be suspected in any infant &lt;1 month of age who presents with clinical findings of sepsis. The most commonly reported signs are fever (rectal temperature &gt;38&ordm;C), hypothermia (rectal temperature &lt;36&ordm;C), irritability, and poor feeding or feeding intolerance. Bulging fontanelle and nuchal rigidity are observed in a minority of infants. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory features characteristic of neonatal bacterial meningitis include isolation of a bacterial pathogen from the cerebrospinal fluid (CSF), increased CSF white blood cell (WBC) count with a predominance of polymorphonuclear leukocytes, elevated CSF protein concentration, and decreased CSF glucose concentration. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of neonates with suspected sepsis or meningitis should include a review of the prenatal history, delivery, complete physical examination, and a full laboratory evaluation for sepsis including a lumbar puncture. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Isolation of a bacterial pathogen from the CSF by culture is the only way to confirm the diagnosis of neonatal bacterial meningitis. Pending culture results, neonates who have undergone evaluation for sepsis and meningitis should be hospitalized and treated with antibiotics for presumed sepsis and meningitis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment and outcome of bacterial meningitis in the neonate\", section on 'Empirical therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The differential diagnosis of bacterial meningitis in the neonate includes infectious and noninfectious causes of aseptic meningitis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/1\">",
"      Wenger JD, Hightower AW, Facklam RR, et al. Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. The Bacterial Meningitis Study Group. J Infect Dis 1990; 162:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/2\">",
"      Harvey D, Holt DE, Bedford H. Bacterial meningitis in the newborn: a prospective study of mortality and morbidity. Semin Perinatol 1999; 23:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/3\">",
"      de Louvois J, Halket S, Harvey D. Neonatal meningitis in England and Wales: sequelae at 5 years of age. Eur J Pediatr 2005; 164:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/4\">",
"      Bortolussi R, Krishnan C, Armstrong D, Tovichayathamrong P. Prognosis for survival in neonatal meningitis: clinical and pathologic review of 52 cases. Can Med Assoc J 1978; 118:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/5\">",
"      Chang CJ, Chang WN, Huang LT, et al. Neonatal bacterial meningitis in southern Taiwan. Pediatr Neurol 2003; 29:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/6\">",
"      Smith PB, Cotten CM, Garges HP, et al. A comparison of neonatal Gram-negative rod and Gram-positive cocci meningitis. J Perinatol 2006; 26:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/7\">",
"      Polin RA, Harris MC. Neonatal bacterial meningitis. Semin Neonatol 2001; 6:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/8\">",
"      Holt DE, Halket S, de Louvois J, Harvey D. Neonatal meningitis in England and Wales: 10 years on. Arch Dis Child Fetal Neonatal Ed 2001; 84:F85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/9\">",
"      Wiswell TE, Baumgart S, Gannon CM, Spitzer AR. No lumbar puncture in the evaluation for early neonatal sepsis: will meningitis be missed? Pediatrics 1995; 95:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/10\">",
"      Hristeva L, Booy R, Bowler I, Wilkinson AR. Prospective surveillance of neonatal meningitis. Arch Dis Child 1993; 69:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/11\">",
"      Synnott MB, Morse DL, Hall SM. Neonatal meningitis in England and Wales: a review of routine national data. Arch Dis Child 1994; 71:F75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/12\">",
"      Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/13\">",
"      Jordan HT, Farley MM, Craig A, et al. Revisiting the need for vaccine prevention of late-onset neonatal group B streptococcal disease: a multistate, population-based analysis. Pediatr Infect Dis J 2008; 27:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/14\">",
"      Fanaroff AA, Korones SB, Wright LL, et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Pediatr Infect Dis J 1998; 17:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/15\">",
"      Barton L, Hodgman JE, Pavlova Z. Causes of death in the extremely low birth weight infant. Pediatrics 1999; 103:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/16\">",
"      GROOVER RV, SUTHERLAND JM, LANDING BH. Purulent meningitis of newborn infants. Eleven-year experience in the antibiotic era. N Engl J Med 1961; 264:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/17\">",
"      Overall JC Jr. Neonatal bacterial meningitis. Analysis of predisposing factors and outcome compared with matched control subjects. J Pediatr 1970; 76:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/18\">",
"      Kelly S. Septicemia in galactosemia. JAMA 1971; 216:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/19\">",
"      Levy HL, Sepe SJ, Shih VE, et al. Sepsis due to Escherichia coli in neonates with galactosemia. N Engl J Med 1977; 297:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/20\">",
"      Unhanand M, Mustafa MM, McCracken GH Jr, Nelson JD. Gram-negative enteric bacillary meningitis: a twenty-one-year experience. J Pediatr 1993; 122:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/21\">",
"      May M, Daley AJ, Donath S, et al. Early onset neonatal meningitis in Australia and New Zealand, 1992-2002. Arch Dis Child Fetal Neonatal Ed 2005; 90:F324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/22\">",
"      Heath PT, Nik Yusoff NK, Baker CJ. Neonatal meningitis. Arch Dis Child Fetal Neonatal Ed 2003; 88:F173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/23\">",
"      Klinger G, Chin CN, Beyene J, Perlman M. Predicting the outcome of neonatal bacterial meningitis. Pediatrics 2000; 106:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/24\">",
"      Gaschignard J, Levy C, Romain O, et al. Neonatal Bacterial Meningitis: 444 Cases in 7 Years. Pediatr Infect Dis J 2011; 30:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/25\">",
"      Stoll BJ, Hansen NI, S&aacute;nchez PJ, et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011; 127:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/26\">",
"      Shattuck KE, Chonmaitree T. The changing spectrum of neonatal meningitis over a fifteen-year period. Clin Pediatr (Phila) 1992; 31:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/27\">",
"      Stoll BJ, Hansen N, Fanaroff AA, et al. To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants. Pediatrics 2004; 113:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/28\">",
"      Shepard CW, Rosenstein NE, Fischer M, Active Bacterial Core Surveillance Team. Neonatal meningococcal disease in the United States, 1990 to 1999. Pediatr Infect Dis J 2003; 22:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/29\">",
"      Goytia VK, Demmler GJ, Pannaraj PS, et al. An unusual cause of sepsis and meningitis in a neonate. Semin Pediatr Infect Dis 2006; 17:187, 225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/30\">",
"      Furyk JS, Swann O, Molyneux E. Systematic review: neonatal meningitis in the developing world. Trop Med Int Health 2011; 16:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/31\">",
"      Pong A, Bradley JS. Bacterial meningitis and the newborn infant. Infect Dis Clin North Am 1999; 13:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/32\">",
"      Weisman LE, Stoll BJ, Cruess DF, et al. Early-onset group B streptococcal sepsis: a current assessment. J Pediatr 1992; 121:428.",
"     </a>",
"    </li>",
"    <li>",
"     Nizet V, Klein JO. Bacterial sepsis and meningitis. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.222.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/34\">",
"      Garges HP, Moody MA, Cotten CM, et al. Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? Pediatrics 2006; 117:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/35\">",
"      Bonadio WA, Stanco L, Bruce R, et al. Reference values of normal cerebrospinal fluid composition in infants ages 0 to 8 weeks. Pediatr Infect Dis J 1992; 11:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/36\">",
"      Doctor BA, Newman N, Minich NM, et al. Clinical outcomes of neonatal meningitis in very-low birth-weight infants. Clin Pediatr (Phila) 2001; 40:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/37\">",
"      Byington CL, Kendrick J, Sheng X. Normative cerebrospinal fluid profiles in febrile infants. J Pediatr 2011; 158:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/38\">",
"      Chadwick SL, Wilson JW, Levin JE, Martin JM. Cerebrospinal fluid characteristics of infants who present to the emergency department with fever: establishing normal values by week of age. Pediatr Infect Dis J 2011; 30:e63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/39\">",
"      Naidoo BT. The cerebrospinal fluid in the healthy newborn infant. S Afr Med J 1968; 42:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/40\">",
"      Rodriguez AF, Kaplan SL, Mason EO Jr. Cerebrospinal fluid values in the very low birth weight infant. J Pediatr 1990; 116:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/41\">",
"      Kestenbaum LA, Ebberson J, Zorc JJ, et al. Defining cerebrospinal fluid white blood cell count reference values in neonates and young infants. Pediatrics 2010; 125:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/42\">",
"      Ansong AK, Smith PB, Benjamin DK, et al. Group B streptococcal meningitis: cerebrospinal fluid parameters in the era of intrapartum antibiotic prophylaxis. Early Hum Dev 2009; 85:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/43\">",
"      Ahmed A, Hickey SM, Ehrett S, et al. Cerebrospinal fluid values in the term neonate. Pediatr Infect Dis J 1996; 15:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/44\">",
"      Shah SS, Ebberson J, Kestenbaum LA, et al. Age-specific reference values for cerebrospinal fluid protein concentration in neonates and young infants. J Hosp Med 2011; 6:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/45\">",
"      Feigin RD, McCracken GH Jr, Klein JO. Diagnosis and management of meningitis. Pediatr Infect Dis J 1992; 11:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/46\">",
"      Kessler SL, Dajani AS. Listeria meningitis in infants and children. Pediatr Infect Dis J 1990; 9:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/47\">",
"      Greenberg RG, Smith PB, Cotten CM, et al. Traumatic lumbar punctures in neonates: test performance of the cerebrospinal fluid white blood cell count. Pediatr Infect Dis J 2008; 27:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7928/abstract/48\">",
"      Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6005 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7928=[""].join("\n");
var outline_f7_47_7928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Temperature instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Interpretation of CSF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cell count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Glucose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Gram stain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Traumatic LP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6005\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6005|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/19/36158\" title=\"table 1\">",
"      Normal cerebrospinal fluid indices neonate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=related_link\">",
"      Clinical features and diagnosis of galactosemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1736?source=related_link\">",
"      Clinical manifestations and diagnosis of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/46/31465?source=related_link\">",
"      Management and complications of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2552?source=related_link\">",
"      Management of the infant whose mother has received group B streptococcal chemoprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=related_link\">",
"      Neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24246?source=related_link\">",
"      Neurologic complications of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13321?source=related_link\">",
"      Pasteurella infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16121?source=related_link\">",
"      Treatment and outcome of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_47_7929="Management of celiac disease in children";
var content_f7_47_7929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of celiac disease in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/47/7929/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/47/7929/contributors\">",
"     Ivor D Hill, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/47/7929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/47/7929/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/47/7929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/47/7929/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/47/7929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is a condition in which there is abnormal small intestinal mucosa that improves morphologically when treated with a gluten-free diet and relapses when gluten is reintroduced. The disorder is commonly referred to as \"celiac sprue\" or \"gluten-sensitive enteropathy\" in the United States. It was first described by Samuel Gee in 1887 in a report entitled \"On the Coeliac Affection,\" although a similar description of a chronic malabsorptive disorder by Aretaeus from Cappadocia (now Turkey) was recorded as far back as the second century AD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The six key elements in the management of patients with celiac disease can be summarized with the following acronym [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Consultation with a skilled dietitian",
"     </li>",
"     <li>",
"      Education about the disease",
"     </li>",
"     <li>",
"      Lifelong adherence to a gluten-free diet",
"     </li>",
"     <li>",
"      Identification and treatment of nutritional deficiencies",
"     </li>",
"     <li>",
"      Access to an advocacy group",
"     </li>",
"     <li>",
"      Continuous long-term follow-up by a multidisciplinary team",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of the patient with celiac disease begins with dietary counseling. Other issues that need to be considered include addressing nutritional needs (including the prevention of bone loss), monitoring of the response, and evaluating patients who do not respond.",
"   </p>",
"   <p>",
"    The management of celiac disease and its complications are reviewed here. Its pathogenesis, clinical manifestations, and diagnosis are discussed separately. This topic is also discussed in an official position statement issued by the American Gastroenterological Association [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/3\">",
"     3",
"    </a>",
"    ]. The discussion below reflects a 2004 consensus statement issued by the National Institutes of Health [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/2\">",
"     2",
"    </a>",
"    ] and guidelines developed by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/4\">",
"     4",
"    </a>",
"    ]. The pediatric guidelines are also available on the NASPGHAN Web site (",
"    <a class=\"external\" href=\"file://www.naspghan.org/\">",
"     www.naspghan.org",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHOM TO TREAT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Presumptive celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with a gluten-free diet is recommended for both diagnostic and therapeutic purposes for all children in one of the following groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with characteristic findings on intestinal biopsy and symptoms consistent with celiac disease (including nonspecific symptoms such as constipation or abdominal pain).",
"     </li>",
"     <li>",
"      Children with characteristic findings on intestinal biopsy and belonging to a high-risk group (eg, relatives of patients with established celiac disease, or patients with type 1 diabetes), whether or not there are associated symptoms (",
"      <a class=\"graphic graphic_table graphicRef50751 \" href=\"UTD.htm?41/53/42844\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with dermatitis herpetiformis confirmed by skin biopsy, with or without associated pathology of the small intestinal mucosa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with a gluten-free diet improves gastrointestinal symptoms as well as most of the non-gastrointestinal symptoms of celiac disease, and may reduce the risk of gastrointestinal malignancies, infertility, and low-birthweight offspring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Latent/potential celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are diagnosed with gluten sensitivity by a positive tissue transglutaminase or IgA endomysial antibody, but who have a normal small bowel biopsy, are considered to have latent or potential celiac disease. Such patients are currently not advised to be on a gluten-free diet but should continue to be monitored and rebiopsied if symptoms develop.",
"   </p>",
"   <p>",
"    Before considering a patient to have latent celiac disease, it is important to make sure that the intestinal biopsies were adequate. The histologic abnormalities of celiac disease can be patchy, so multiple biopsies must be taken from both the distal duodenum and duodenal bulb, and these should be evaluated by an expert pathologist [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, we generally perform further serological testing using a second specific antibody (eg, antiendomysial antibodies). HLA testing may also be helpful; if the patient has neither the DQ2 nor DQ8 genotype, the likelihood of having celiac disease is very low. Because a child may not effectively communicate about symptoms that may herald active disease, periodic reevaluation for symptoms and growth is important, and an additional endoscopy with biopsies should be performed when appropriate in high-risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF A GLUTEN-FREE DIET",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornerstone of treatment of celiac disease is the elimination of gluten in the diet. The principle sources of dietary gluten are wheat, rye, and barley. The toxicity of oats in celiac disease is now in doubt. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Oats'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cereal chemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much work has been undertaken to characterize the toxic cereal fraction within wheat flour that is associated with celiac disease. The term gluten is used to describe the protein fraction of wheat flour, often referred to as prolamins due to the high content of the amino acids proline and glutamine. Gluten can be divided into an alcohol-soluble fraction, gliadin, and an alcohol-insoluble fraction, glutenin. Prolamins from other cereals are secalins from rye and hordeins from barley. The term gluten is often used loosely to refer to all prolamins found in wheat, rye, and barley.",
"   </p>",
"   <p>",
"    The taxonomic relationship between the major cereal grains provides a framework upon which their toxicity in celiac disease can be predicted (",
"    <a class=\"graphic graphic_figure graphicRef57365 \" href=\"UTD.htm?8/2/8239\">",
"     figure 1",
"    </a>",
"    ). As an example, wheat, rye, and barley belong to the tribe known as Triticeae, while oats belong to a neighboring tribe (Aveneae). Thus, avenin (the major prolamin in oats) is genetically less similar to gluten than gluten is to secalin and hordein. However, despite the greater genetic difference, the prolamins from oats, barley, wheat, and rye have immunologic crossreactivity, reflecting their common ancestry [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The antibodies that are raised against gluten proteins are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link&amp;anchor=H34#H34\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\", section on 'How to test'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Oats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gluten, secalins, and hordeins are toxic to patients with celiac disease. The toxicity of oats is less clear because some studies suggest that pure oat flour can be tolerated without disease recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Oats contain a sequence homology (ie, QQQPF) with gliadin peptides, which have been shown to be disease-activating [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, this homology may not be relevant since T-cell activation requires larger epitopes; in addition, oats contain a relatively smaller proportion of this toxic prolamin moiety compared with other gluten-containing cereals. Indeed, some studies suggest that tolerance to oats depends at least in part on the total amount consumed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/14\">",
"     14",
"    </a>",
"    ]. Daily oats consumption less than 40 to 60",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    by patients whose celiac disease is in remission appears to be well tolerated, while larger daily intake is associated with disease recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several randomized studies in adults suggest that oats caused no differences in nutritional status, symptoms, or laboratory or histologic measures after one or five years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/8,15,16\">",
"     8,15,16",
"    </a>",
"    ]. However, in another study, patients consuming oats had significantly more gastrointestinal symptoms (including diarrhea and constipation) and had a significantly higher density of intraepithelial lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/17\">",
"     17",
"    </a>",
"    ]. A metaanalysis of 10 studies concluded that there is no good evidence that consumption of oats causes mucosal damage in patients with celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/18\">",
"     18",
"    </a>",
"    ]. Among 165 patients included in the study, only one developed histological changes.",
"   </p>",
"   <p>",
"    Few studies have addressed the safety of oats in children with celiac disease. One small open-label study suggested that oats may be safe [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/19\">",
"     19",
"    </a>",
"    ]. A larger controlled trial randomly assigned 116 children with newly diagnosed celiac disease to a standard gluten-free diet, or a gluten-free diet in which additional wheat-free oat products were permitted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/20\">",
"     20",
"    </a>",
"    ]. Median daily oat intake was 16 g. All patients were in clinical remission at the end of the study (one year). There were no significant differences in clinical, histologic, or biochemical markers of disease activity.",
"   </p>",
"   <p>",
"    Despite these observations, the long-term safety of oat consumption in patients with celiac disease is uncertain, and most studies that examined the safety of oats have included patients with relatively mild disease or whose disease was in remission upon reinstitution of oats in the diet. Furthermore, some patients may be exquisitely sensitive to oat prolamins. Thus, at the present time, a reasonable approach is to limit oat consumption to 50 to 60",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (approximately 2 oz) in patients with mild disease upon presentation or whose disease is in remission after a stringent gluten-free diet. The patients should be followed carefully for clinical or serologic evidence of disease recurrence after reintroducing oats. Patients with severe disease should probably avoid oats altogether. Oats also should be avoided if the purity cannot be guaranteed, as contamination with even small amounts of other cereals can cause damage to the intestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     NUTRITIONAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dietary counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumption of a gluten-free diet requires a major lifestyle change since gluten is contained in a variety of foods that are commonly consumed in a Western diet. Thus, it is helpful to provide written information and dietary counseling to improve compliance. A number of resources are available for patients with celiac disease including a variety of cookbooks, gluten-free prepared foods, and Internet sites (",
"    <a class=\"external\" href=\"file://www.csaceliacs.org/\">",
"     www.csaceliacs.org",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.celiac.com/\">",
"     www.celiac.com",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"     \"Patient information: Celiac disease in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As general rules, the following advice can be given to all patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Foods containing wheat, rye, and barley should be avoided.",
"     </li>",
"     <li>",
"      Soybean or tapioca flours, rice, corn, buckwheat, and potatoes are safe.",
"     </li>",
"     <li>",
"      Read labels on prepared foods and condiments carefully, paying particular attention to additives such as stabilizers or emulsifiers that may contain gluten.",
"     </li>",
"     <li>",
"      Dairy products should be avoided initially since many patients with celiac disease have secondary lactose intolerance. Most children will tolerate lactose after mucosal healing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"       \"Lactose intolerance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advice regarding consumption of oats is discussed above. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Oats'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is some disagreement over the strict definition and product labeling of gluten-free foods. Currently, foods must contain no more than 20 ppm gluten to be considered gluten-free [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Is strict gluten avoidance necessary?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because gluten elimination poses several lifestyle restrictions, many patients ask whether small to moderate amounts of gluten in the diet are permissible. Furthermore, some patients consider symptoms to be sufficiently mild so as not to warrant the sacrifice of fastidiously avoiding gluten-containing foods. The problem is even greater among asymptomatic patients in whom celiac disease was diagnosed based upon antibody screening. The benefit of rigid gluten avoidance has not been proven since the natural history of celiac disease in such patients is unclear.",
"   </p>",
"   <p>",
"    Several arguments favor encouraging strict adherence to a gluten-free diet in most patients with established celiac disease regardless of clinical symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite feeling clinically well, patients may have a variety of micronutrient deficiencies that may ultimately have clinical sequelae (such as bone loss due to vitamin D deficiency) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/22\">",
"       22",
"      </a>",
"      ]. (See below).",
"     </li>",
"     <li>",
"      Multiple reports have suggested increased overall mortality (mostly from gastrointestinal malignancies) in patients with celiac disease compared to the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]. Several studies have suggested the risk is decreased in patients adhering to a gluten-free diet [",
"      <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/26-29\">",
"       26-29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The likelihood that patients with celiac disease will develop other autoimmune disorders that have been associated with celiac disease (such as type 1 diabetes mellitus, connective tissue diseases, Hashimoto's thyroiditis, and Graves' disease) appeared to be related to the duration of exposure to gluten in at least one study [",
"      <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/30\">",
"       30",
"      </a>",
"      ], but a causal relation has not been established. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link&amp;anchor=H28#H28\">",
"       \"Clinical manifestations and diagnosis of celiac disease in children\", section on 'Diabetes mellitus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mothers with untreated celiac disease are at increased risk for having low birth weight newborns and preterm births [",
"      <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the benefit of rigid gluten avoidance has not been proven, the above considerations lead us to recommend a strict gluten-free diet for any patients with established celiac disease, even if small amounts of gluten do not cause symptoms. A review of the literature by an expert panel concluded that the lower threshold of gliadin intake that causes mucosal damage is between 10 and 100 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Micronutrient deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An individual patient's overall nutritional status should be considered so that nutritional and caloric deficiencies can be adequately supplemented. Specific dietary deficiency such as iron,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    , calcium, vitamin D, and, rarely, vitamin B12 deficiency should be corrected. A gluten-free diet may induce troublesome constipation since it is low in roughage. This usually responds to the addition of dietary rice bran and ispaghula husks;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/34/1573?source=see_link\">",
"     psyllium",
"    </a>",
"    fiber or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    supplements are also generally gluten-free. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22279?source=see_link\">",
"     \"Overview of the treatment of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prevention of bone loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone loss (principally osteopenia and less often osteoporosis) is common in celiac disease, and can occur in patients without gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/22,34-36\">",
"     22,34-36",
"    </a>",
"    ]. Much of the bone loss is related to secondary hyperparathyroidism, which is probably due to vitamin D deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with celiac disease have reduced bone mass at the time of diagnosis, similar to adults with newly diagnosed celiac disease. However, children are more likely than adults to have fully restored bone mass after 6 to 12 months of a gluten-free diet [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Therefore, the AGA guidelines suggest that DEXA scans are unnecessary in children with newly diagnosed uncomplicated celiac disease.",
"   </p>",
"   <p>",
"    Recommendations for the prevention and treatment of osteoporosis in patients with celiac disease also have been proposed by the British Society of Gastroenterology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .) The American Gastroenterological Association (AGA) guideline for osteoporosis in gastrointestinal diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/41\">",
"     41",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA Web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MONITORING THE RESPONSE TO A GLUTEN-FREE DIET",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rapidity of the response to a gluten-free diet is variable. Approximately 70 percent of patients have noticeable clinical improvement within two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/42\">",
"     42",
"    </a>",
"    ]. As a general rule, symptoms improve faster than histology, especially when biopsies are obtained in the proximal intestine. The reason is incompletely understood; however, a likely explanation is that the less severely damaged distal small intestine recovers faster than the proximal intestine, which typically is affected more severely because of relatively increased exposure to gluten [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antibody testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest measurement of celiac-specific antibodies (tissue transglutaminase or antiendomysial antibodies) about six months after beginning a gluten-free diet. A decrease in the antibody titer, with eventual disappearance in most individuals, is an indirect indicator of dietary adherence and recovery. In one series, 35 percent of children with CD became seronegative for tissue transglutaminase within six months of beginning a gluten-free diet, and 55 percent were seronegative within 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/44\">",
"     44",
"    </a>",
"    ]. We also measure antibodies in children with persistent or recurrent symptoms at any time after starting a gluten-free diet. A rise in antibody levels may indicate that the individual is knowingly or inadvertently ingesting gluten again, and should prompt careful review of the diet. If patients remain asymptomatic, we measure antibodies annually to monitor adherence to the gluten-free diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for a follow-up biopsy in patients with clinical improvement has been debated, especially since serologic testing can be used to monitor recovery and compliance with the diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .) We suggest NOT repeating a biopsy in patients with a definite diagnosis of celiac disease who have all of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms suggestive of celiac disease and elevated tissue transglutaminase, or anti-endomysial antibodies at presentation.",
"     </li>",
"     <li>",
"      Initial intestinal biopsy with histologic changes characteristic of celiac disease (Marsh type 3 villous atrophy).",
"     </li>",
"     <li>",
"      Resolution of symptoms and marked decrease in tissue transglutaminase antibodies on a gluten-free diet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This recommendation is consistent with NASPGHAN guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For children in whom the diagnosis is less certain because they do not meet one or more of the above characteristics, we suggest a second small intestinal biopsy 9 to 12 months after beginning a gluten-free diet to demonstrate histologic improvement. Although histologic improvement is usually seen by this time, persistent abnormalities have been described, even in patients with symptomatic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The significance is at the moment unclear, but in many cases the abnormalities do not appear to be linked with dietary problems. After checking for dietary non-compliance or inadvertent ingestion of gluten, other causes of villous atrophy should be considered in these patients. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Patients with other disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gluten rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gluten rechallenge (a traditional approach to diagnosis of celiac disease) is generally not required unless the diagnosis remains uncertain. Guidelines issued by the European Society of Paediatric Gastroenterology and Nutrition suggested that gluten rechallenge is not mandatory in patients with good improvement in symptoms, histology, and a decline in the titer of antiendomysial antibodies (which usually return to normal in three to six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/47\">",
"     47",
"    </a>",
"    ]. Gluten rechallenge was also considered to be unnecessary in consensus statements issued by the National Institutes of Health [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/2\">",
"     2",
"    </a>",
"    ] and NASPGHAN [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Furthermore, a rare hazard in giving a gluten rechallenge is the development of fulminant diarrhea, with resulting dehydration, acidosis, and other metabolic disturbances (a condition known as \"gliadin shock\") [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/48\">",
"     48",
"    </a>",
"    ]. Such patients should be treated with corticosteroids.",
"   </p>",
"   <p>",
"    When gluten rechallenge is chosen for patients in whom the diagnosis remains uncertain, the patient is asked to ingest at least 10 g of gluten per day (an amount contained in four slices of regular bread) for four to six weeks, followed by endoscopic biopsies. The biopsy date should be advanced in patients who develop severe symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PNEUMOCOCCAL VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is associated with hyposplenism. As a result, children with celiac disease should be immunized with a pneumococcal vaccine. In the United States, most children are immunized during infancy with the conjugate vaccine. Like other children who are at increased risk for invasive pneumococcal disease, children with celiac disease should receive an additional series of polysaccharide vaccine as appropriate for their age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NONRESPONDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with celiac disease respond to a gluten-free diet. The most common reasons for a lack of response are poor compliance or inadvertent gluten ingestion (",
"    <a class=\"graphic graphic_table graphicRef79790 \" href=\"UTD.htm?32/1/32796\">",
"     table 2",
"    </a>",
"    ). Thus, a meticulous dietary history should be obtained, and dietary counseling pursued with an experienced dietitian in patients who continue to have symptoms or persistent histologic abnormalities, or in those in whom serum antibody titers have not declined.",
"   </p>",
"   <p>",
"    Trace amounts of gluten may be contained in products that are labeled as gluten-free. However, the small amount of gluten contained in these products does not necessarily translate into refractory disease. A study evaluating occult gluten intake (from grain contaminants) among 76 patients on a gluten-free diet estimated that gluten contamination of up to 100 parts per million (up to a total of 30 mg per day) did not result in histologic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/51\">",
"     51",
"    </a>",
"    ]. Interestingly, 13 of 59 naturally gluten-free products and 11 of 24 wheat starch-based gluten-free products contained gluten ranging from 20 to 200",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    Medications (pills) generally contain minimal gluten and do not need to be avoided.",
"   </p>",
"   <p>",
"    Patients who do not respond despite adherence to a gluten-free diet fall into three main categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with clinical or histologic features that are caused by other disorders",
"     </li>",
"     <li>",
"      Patients with refractory sprue",
"     </li>",
"     <li>",
"      Patients with ulcerative jejunitis or intestinal lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5256?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another consideration in incomplete responders or nonresponders is that not all clinical features of celiac disease respond at the same rate. Furthermore, bone loss caused by secondary hyperparathyroidism and peripheral neuropathy may improve only partially despite a gluten-free diet [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Dermatitis herpetiformis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patients with other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other diagnoses should be considered in patients who, despite apparent compliance, continue to have symptoms or do not have histologic improvement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As mentioned above, concomitant or secondary lactose intolerance is a possible cause of continued diarrhea and flatulence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"       \"Lactose intolerance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with celiac disease are susceptible to common bowel disturbances such as irritable bowel syndrome, which affects a large proportion of the general population and may present with features suggestive of malabsorption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=see_link\">",
"       \"Clinical manifestations and diagnosis of irritable bowel syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"       \"Clinical features and diagnosis of malabsorption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A small percentage of patients develop small bowel bacterial overgrowth, which may respond to antibiotics [",
"      <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=see_link\">",
"       \"Treatment of small intestinal bacterial overgrowth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of diseases associated with small bowel villous atrophy also should be excluded in patients with persistent symptoms who do not show histologic improvement (",
"      <a class=\"graphic graphic_table graphicRef60030 \" href=\"UTD.htm?16/1/16411\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"       \"Clinical features and diagnosis of malabsorption\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Refractory sprue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory sprue (also referred to as \"unclassified sprue\") occurs almost exclusively in adults. These patients fall into two clinical categories [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients who have no initial response to a gluten-free diet",
"     </li>",
"     <li>",
"      Patients who experience initial clinical improvement on a gluten-free diet, but, after a period of remission, develop disease refractory to gluten abstinence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Refractory sprue can be severe and associated with progressive malabsorption and death. A subset of patients develop subepithelial collagen deposition, a condition referred to as \"collagenous sprue\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/55\">",
"     55",
"    </a>",
"    ]. The diagnostic workup and management of patients with refractory sprue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of celiac disease in adults\", section on 'Refractory sprue'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DERMATITIS HERPETIFORMIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is associated with a number of skin disorders of which dermatitis herpetiformis is the most common (",
"    <a class=\"graphic graphic_table graphicRef71271 \" href=\"UTD.htm?3/19/3387\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/56\">",
"     56",
"    </a>",
"    ]. Dermatitis herpetiformis is characterized by an itchy papular vesicular eruption usually located symmetrically on the elbows, knees, buttocks, sacrum, face, neck, trunk and occasionally within the mouth (",
"    <a class=\"graphic graphic_picture graphicRef74915 graphicRef70783 \" href=\"UTD.htm?4/63/5111\">",
"     picture 1A-B",
"    </a>",
"    ). The predominant symptoms are itching and burning that are rapidly relieved with rupture of the blisters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=see_link&amp;anchor=H1643384077#H1643384077\">",
"     \"Dermatitis herpetiformis\", section on 'Clinical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improvement in dermatitis herpetiformis following withdrawal of gluten may be considerably delayed (6 to 12 months) compared to the response of the intestinal manifestations of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/57\">",
"     57",
"    </a>",
"    ]. As a result, treatment usually includes medical therapy (such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/31/34288?source=see_link\">",
"     dapsone",
"    </a>",
"    ) in addition to gluten avoidance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7929/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=see_link&amp;anchor=H1643384165#H1643384165\">",
"     \"Dermatitis herpetiformis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=see_link&amp;anchor=H21110581#H21110581\">",
"     \"Dermatitis herpetiformis\", section on 'Treatment of children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/9/25746?source=see_link\">",
"       \"Patient information: Gluten-free diet (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/14/11492?source=see_link\">",
"       \"Patient information: Celiac disease in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is a genetically determined sensitivity to dietary gluten, which causes intestinal inflammation and loss of villous surface area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with serologically and histologically confirmed celiac disease and compatible clinical or laboratory manifestations should adhere to a gluten-free diet. For patients with symptoms, we recommend strict avoidance of gluten (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with few or no symptoms, but with histologic evidence of celiac disease, we also suggest strict gluten avoidance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This suggestion recognizes there are no controlled trials examining the long-term effects of a gluten-free diet in asymptomatic patients, or comparing a low-gluten diet to a gluten-free diet, and that quality of life may be adversely affected by the dietary regimen. The diet should be guided by in-depth consultation with an expert dietitian. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Is strict gluten avoidance necessary?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A gluten-free diet requires strict avoidance of wheat, rye, and barley. Whether oat products can be safely included in a gluten-free diet is controversial. For patients with disease that is mild or in remission, we suggest limiting oat consumption to 50 to 60",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      (approximately 2 oz) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These patients should be followed carefully for clinical or serologic evidence of disease recurrence after reintroducing oats. For patients with severe disease, we suggest avoiding oats altogether (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Oats'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with positive tests for tissue transglutaminase or anti-endomysial antibodies, but normal results of small bowel biopsies, are considered to have \"latent\" or \"potential\" celiac disease. We suggest NOT treating such patients with a gluten-free diet (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, it is important that histologically evident celiac disease was adequately evaluated in such patients with multiple intestinal biopsies since the histologic abnormalities can be patchy. These patients should be carefully monitored for growth failure and other symptoms that might suggest active celiac disease, and should be rebiopsied if symptoms develop (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Latent/potential celiac disease'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Celiac disease is associated with hyposplenism. We suggest that patients with celiac disease receive pneumococcal vaccine as indicated for other patients with increased risk for invasive pneumococcal disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pneumococcal vaccination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"   </p>",
"   <p>",
"    We use the following approach to monitor a patient with celiac disease after establishment of a gluten-free diet, as outlined in the NASPGHAN guidelines. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Monitoring the response to a gluten-free diet'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific serologic testing should be repeated after six months on a gluten-free diet. A decrease in the antibody titer indicates adherence to the diet and supports the diagnosis of celiac disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Antibody testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When patients present with typical symptoms, have characteristic laboratory and histological findings, and respond well to a gluten-free diet, as measured by symptoms and antibodies, the diagnosis of celiac disease is clearly established. For these patients, we do not repeat the duodenal biopsy after beginning a gluten-free diet. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who do not meet all of the criteria above, the diagnosis of celiac disease is less firmly established. For these patients, we generally perform a second biopsy after 9 to 12 months of a strict gluten-free diet. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rechallenging the patient with gluten is no longer required to establish a diagnosis of celiac disease. However, gluten rechallenge may be helpful for selected patients in whom the diagnosis remains ambiguous after a trial of a gluten-free diet. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Gluten rechallenge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with celiac disease respond to a gluten-free diet. The most common reasons for lack of response are poor compliance or inadvertent gluten ingestion (",
"      <a class=\"graphic graphic_table graphicRef79790 \" href=\"UTD.htm?32/1/32796\">",
"       table 2",
"      </a>",
"      ). All patients with celiac disease should be reevaluated periodically. The evaluation should include assessment of growth, gastrointestinal and other symptoms associated with celiac disease, and the patient's understanding of and compliance with the gluten-free diet. We measure tissue transglutaminase or other specific antibodies annually, and in patients with persistent or recurrent symptoms. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Monitoring the response to a gluten-free diet'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Adams F. The extant works of Aretaeus the Cappadocian, London Sydenham Society, 1856.",
"    </li>",
"    <li>",
"     National Institutes of Health Consensus Development Conference Statement. Celiac Disease 2004. Available at: file://consensus.nih.gov/ (Accessed on March 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/3\">",
"      AGA Institute. AGA Institute Medical Position Statement on the Diagnosis and Management of Celiac Disease. Gastroenterology 2006; 131:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/4\">",
"      Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/5\">",
"      Ravelli A, Bolognini S, Gambarotti M, Villanacci V. Variability of histologic lesions in relation to biopsy site in gluten-sensitive enteropathy. Am J Gastroenterol 2005; 100:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/6\">",
"      Freedman AR, Galfre G, Gal E, et al. Western immunoblotting of cereal proteins with monoclonal antibodies to wheat gliadin to investigate coeliac disease. Int Arch Allergy Appl Immunol 1988; 85:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/7\">",
"      Troncone R, Auricchio S, De Vincenzi M, et al. An analysis of cereals that react with serum antibodies in patients with coeliac disease. J Pediatr Gastroenterol Nutr 1987; 6:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/8\">",
"      Janatuinen EK, Pikkarainen PH, Kemppainen TA, et al. A comparison of diets with and without oats in adults with celiac disease. N Engl J Med 1995; 333:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/9\">",
"      Srinivasan U, Leonard N, Jones E, et al. Absence of oats toxicity in adult coeliac disease. BMJ 1996; 313:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/10\">",
"      Hardman CM, Garioch JJ, Leonard JN, et al. Absence of toxicity of oats in patients with dermatitis herpetiformis. N Engl J Med 1997; 337:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/11\">",
"      Holm K, M&auml;ki M, Vuolteenaho N, et al. Oats in the treatment of childhood coeliac disease: a 2-year controlled trial and a long-term clinical follow-up study. Aliment Pharmacol Ther 2006; 23:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/12\">",
"      Sturgess R, Day P, Ellis HJ, et al. Wheat peptide challenge in coeliac disease. Lancet 1994; 343:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/13\">",
"      Shidrawi RG, Day P, Przemioslo R, et al. In vitro toxicity of gluten peptides in coeliac disease assessed by organ culture. Scand J Gastroenterol 1995; 30:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/14\">",
"      Schmitz J. Lack of oats toxicity in coeliac disease. BMJ 1997; 314:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/15\">",
"      Janatuinen EK, Kemppainen TA, Pikkarainen PH, et al. Lack of cellular and humoral immunological responses to oats in adults with coeliac disease. Gut 2000; 46:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/16\">",
"      Janatuinen EK, Kemppainen TA, Julkunen RJ, et al. No harm from five year ingestion of oats in coeliac disease. Gut 2002; 50:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/17\">",
"      Per&auml;aho M, Kaukinen K, Mustalahti K, et al. Effect of an oats-containing gluten-free diet on symptoms and quality of life in coeliac disease. A randomized study. Scand J Gastroenterol 2004; 39:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/18\">",
"      Thacker SB. Public health surveillance and the prevention of injuries in sports: what gets measured gets done. J Athl Train 2007; 42:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/19\">",
"      Hoffenberg EJ, Haas J, Drescher A, et al. A trial of oats in children with newly diagnosed celiac disease. J Pediatr 2000; 137:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/20\">",
"      H&ouml;gberg L, Laurin P, F&auml;lth-Magnusson K, et al. Oats to children with newly diagnosed coeliac disease: a randomised double blind study. Gut 2004; 53:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/21\">",
"      Thompson T. Gluten contamination of commercial oat products in the United States. N Engl J Med 2004; 351:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/22\">",
"      Shaker JL, Brickner RC, Findling JW, et al. Hypocalcemia and skeletal disease as presenting features of celiac disease. Arch Intern Med 1997; 157:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/23\">",
"      Hardwick C. Prognosis in coeliac disease: A Review of Seventy-Three Cases. Arch Dis Child 1939; 14:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/24\">",
"      Logan RF, Rifkind EA, Turner ID, Ferguson A. Mortality in celiac disease. Gastroenterology 1989; 97:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/25\">",
"      Nielsen OH, Jacobsen O, Pedersen ER, et al. Non-tropical sprue. Malignant diseases and mortality rate. Scand J Gastroenterol 1985; 20:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/26\">",
"      Holmes GK, Prior P, Lane MR, et al. Malignancy in coeliac disease--effect of a gluten free diet. Gut 1989; 30:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/27\">",
"      Corrao G, Corazza GR, Bagnardi V, et al. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet 2001; 358:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/28\">",
"      Askling J, Linet M, Gridley G, et al. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002; 123:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/29\">",
"      Collin P, Reunala T, Pukkala E, et al. Coeliac disease--associated disorders and survival. Gut 1994; 35:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/30\">",
"      Ventura A, Magazz&ugrave; G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology 1999; 117:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/31\">",
"      N&oslash;rg&aring;rd B, Fonager K, S&oslash;rensen HT, Olsen J. Birth outcomes of women with celiac disease: a nationwide historical cohort study. Am J Gastroenterol 1999; 94:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/32\">",
"      Ludvigsson JF, Montgomery SM, Ekbom A. Celiac disease and risk of adverse fetal outcome: a population-based cohort study. Gastroenterology 2005; 129:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/33\">",
"      Hischenhuber C, Crevel R, Jarry B, et al. Review article: safe amounts of gluten for patients with wheat allergy or coeliac disease. Aliment Pharmacol Ther 2006; 23:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/34\">",
"      Walters JR, Banks LM, Butcher GP, Fowler CR. Detection of low bone mineral density by dual energy x ray absorptiometry in unsuspected suboptimally treated coeliac disease. Gut 1995; 37:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/35\">",
"      Mustalahti K, Collin P, Siev&auml;nen H, et al. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet 1999; 354:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/36\">",
"      Meyer D, Stavropolous S, Diamond B, et al. Osteoporosis in a north american adult population with celiac disease. Am J Gastroenterol 2001; 96:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/37\">",
"      Selby PL, Davies M, Adams JE, Mawer EB. Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res 1999; 14:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/38\">",
"      Mora S, Barera G, Beccio S, et al. A prospective, longitudinal study of the long-term effect of treatment on bone density in children with celiac disease. J Pediatr 2001; 139:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/39\">",
"      Zanchi C, Di Leo G, Ronfani L, et al. Bone metabolism in celiac disease. J Pediatr 2008; 153:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/40\">",
"      Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut 2000; 46 Suppl 1:i1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/41\">",
"      American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/42\">",
"      Pink IJ, Creamer B. Response to a gluten-free diet of patients with the coeliac syndrome. Lancet 1967; 1:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/43\">",
"      MACDONALD WC, BRANDBORG LL, FLICK AL, et al. STUDIES OF CELIAC SPRUE. IV. THE RESPONSE OF THE WHOLE LENGTH OF THE SMALL BOWEL TO A GLUTEN-FREE DIET. Gastroenterology 1964; 47:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/44\">",
"      Hogen Esch CE, Wolters VM, Gerritsen SA, et al. Specific celiac disease antibodies in children on a gluten-free diet. Pediatrics 2011; 128:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/45\">",
"      Lee SK, Lo W, Memeo L, et al. Duodenal histology in patients with celiac disease after treatment with a gluten-free diet. Gastrointest Endosc 2003; 57:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/46\">",
"      Selby WS, Painter D, Collins A, et al. Persistent mucosal abnormalities in coeliac disease are not related to the ingestion of trace amounts of gluten. Scand J Gastroenterol 1999; 34:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/47\">",
"      Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child 1990; 65:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/48\">",
"      KRAINICK HG, DEBATIN F, GAUTIER E, et al. [Additional research on the injurious effect of wheat flour in celiac disease.I. Acute gliadin reaction (gliadin shock)]. Helv Paediatr Acta 1958; 13:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/49\">",
"      Giebink GS. The prevention of pneumococcal disease in children. N Engl J Med 2001; 345:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/50\">",
"      Pelton SI, Klein JO. The future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases in infants and children. Pediatrics 2002; 110:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/51\">",
"      Collin P, Thorell L, Kaukinen K, M&auml;ki M. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? Aliment Pharmacol Ther 2004; 19:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/52\">",
"      Tursi A, Brandimarte G, Giorgetti G. High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal. Am J Gastroenterol 2003; 98:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/53\">",
"      Shah VH, Rotterdam H, Kotler DP, et al. All that scallops is not celiac disease. Gastrointest Endosc 2000; 51:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/54\">",
"      Trier JS, Falchuk ZM, Carey MC, Schreiber DS. Celiac sprue and refractory sprue. Gastroenterology 1978; 75:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/55\">",
"      McCashland TM, Donovan JP, Strobach RS, et al. Collagenous enterocolitis: a manifestation of gluten-sensitive enteropathy. J Clin Gastroenterol 1992; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/56\">",
"      Fry L. Dermatitis herpetiformis. Baillieres Clin Gastroenterol 1995; 9:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7929/abstract/57\">",
"      Garioch JJ, Lewis HM, Sargent SA, et al. 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 1994; 131:541.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5907 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7929=[""].join("\n");
var outline_f7_47_7929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHOM TO TREAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Presumptive celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Latent/potential celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PRINCIPLES OF A GLUTEN-FREE DIET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cereal chemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Oats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NUTRITIONAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dietary counseling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Is strict gluten avoidance necessary?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Micronutrient deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prevention of bone loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MONITORING THE RESPONSE TO A GLUTEN-FREE DIET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antibody testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gluten rechallenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PNEUMOCOCCAL VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NONRESPONDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patients with other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Refractory sprue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DERMATITIS HERPETIFORMIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5907\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5907|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/2/8239\" title=\"figure 1\">",
"      Taxonomy cereal grains",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5907|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/2/30753\" title=\"picture 1A\">",
"      Dermatitis herpetiformis AGA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/62/39905\" title=\"picture 1B\">",
"      Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5907|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/53/42844\" title=\"table 1\">",
"      Prevalence of celiac disease in special populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/1/32796\" title=\"table 2\">",
"      Foods products with gluten",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/1/16411\" title=\"table 3\">",
"      Differential diagnosis of small intestinal villous atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/19/3387\" title=\"table 4\">",
"      Skin disorders associated with celiac disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22455?source=related_link\">",
"      Clinical manifestations and diagnosis of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5256?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=related_link\">",
"      Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22279?source=related_link\">",
"      Overview of the treatment of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=related_link\">",
"      Patient information: Celiac disease in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/14/11492?source=related_link\">",
"      Patient information: Celiac disease in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/9/25746?source=related_link\">",
"      Patient information: Gluten-free diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=related_link\">",
"      Treatment of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_47_7930="Management of healthcare personnel exposed to HIV";
var content_f7_47_7930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of healthcare personnel exposed to HIV",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/47/7930/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/47/7930/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/47/7930/contributors\">",
"     David J Weber, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/47/7930/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/47/7930/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/47/7930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/47/7930/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/47/7930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potentially grave consequences of exposure to body fluids from people infected with HIV have prompted development of policies and procedures designed to reduce the risk in healthcare personnel (HCP). The most important practice is the use of available measures to prevent such exposures. Although the incidence of needlestick injuries has been reduced by advances in education, needle disposal, engineering changes (eg, needleless devices, safety needles) and personnel protection, institutions and healthcare professionals must continue to assume responsibility in further lowering the risk.",
"   </p>",
"   <p>",
"    The procedures to follow after HCP have had significant contact with body fluids from a patient infected with HIV are reviewed here. The epidemiology of bloodborne exposures in HCP, the Occupational Safety and Health Administration (OSHA) requirements regarding infection control procedures and training in the United States, and the management of potential exposure to other bloodborne pathogens including hepatitis B and hepatitis C virus are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management and risks associated with nonoccupational exposure to HIV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26410?source=see_link\">",
"     \"Nonoccupational exposure to HIV in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to the risk of transmission of HIV from infected HCP are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42456?source=see_link\">",
"     \"Surgical issues in HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK OF TRANSMISSION OF HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of transmission of HIV infection following inadvertent exposure varies widely depending upon the type of exposure. The risk is increased when the source has a high viral load, the volume is large, and the exposure is deep. The healthcare personnel (HCP) at highest risk are those who have percutaneously been inoculated with blood from an HIV-infected source. All known seroconversions have occurred with exposure to blood, bloody fluids, or viral cultures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28866473\">",
"    <span class=\"h2\">",
"     Risk by exposure type",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of becoming infected with HIV after exposure to body fluids from an HIV-infected patient is low. A review of prospective studies of seroconversion following occupational exposure to an HIV-infected source in the era before the introduction of highly active antiretroviral therapy (HAART) found the following [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HIV transmission occurred in 20 of 6135 cases (0.33 percent) following percutaneous exposure",
"     </li>",
"     <li>",
"      One case of HIV was transmitted out of 1143 exposures (0.09 percent) on the mucosa of HCP",
"     </li>",
"     <li>",
"      There were no cases after 2712 intact skin exposures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar frequency of HIV seroconversion after needlestick injury (0.36 percent) was found in a later report from the Centers for Disease Control and Prevention (CDC) Cooperative Needlestick Surveillance Group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/2\">",
"     2",
"    </a>",
"    ] and in another meta-analysis (0.23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/3\">",
"     3",
"    </a>",
"    ]. The risk of HIV infection following an occupational mucosal exposure was subsequently estimated to be 0.03 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors for seroconversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A CDC case-control study of needlestick injuries from an HIV-infected source in the United States, the United Kingdom, France, and Italy included 33 cases who seroconverted and 655 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/5\">",
"     5",
"    </a>",
"    ]. The study found that the following factors, each of which presumably reflected exposure to a higher number of viral particles, increased the risk of acquiring HIV after a needlestick injury:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deep injury (odds ratio [OR] 15)",
"     </li>",
"     <li>",
"      A device visibly contaminated with the patient's blood (OR 6.2)",
"     </li>",
"     <li>",
"      Needle placement in a vein or artery (OR 4.3)",
"     </li>",
"     <li>",
"      Terminal illness in the source patient (OR 5.6)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of cases were injured by a hollow bore as opposed to a solid needle.",
"   </p>",
"   <p>",
"    Based upon the studies of sexual transmission in discordant couples and rates of perinatal transmission, HIV viral load is another important risk factor for transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. The studies cited above did not directly address this issue because they were based upon data obtained before viral load measurement was routinely available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. The observed correlation of transmission risk with a source with late-stage AIDS is thought to be a surrogate for high HIV viral load.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk of exposure by profession",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nurses report the most frequent blood and body exposures (48.6 percent), followed by physicians who are residents or fellows (7.7 percent), attending physicians (7.7 percent), non-lab technologists (4.5 percent), respiratory therapists (3.6 percent), and certified nursing",
"    <span class=\"nowrap\">",
"     assistants/home",
"    </span>",
"    health aides (3.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, long work hours and sleep deprivation among medical trainees result in fatigue, which is associated with a threefold increase in the risk of needle-stick injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/11\">",
"     11",
"    </a>",
"    ]. A survey performed among 699 surgeons-in-training at 17 medical centers found that the mean number of needlestick injuries by the fifth (final) year of residency was 7.7 and that 99 percent of residents had at least one needlestick injury [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, approximately one-half had a needlestick injury involving a high-risk patient, and more than half of the most recent injuries had not been reported; the most common reason was lack of time. Despite the concerning number of exposures in this study, there has never been a confirmed case of HIV transmitted to a surgeon through occupational exposure in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28866504\">",
"    <span class=\"h2\">",
"     Documented seroconversions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of December 2010, 57 HCP in the United States had acquired occupational HIV infection as indicated by seroconversion in the context of an occupational exposure to an HIV-infected source [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Of these, 48 workers sustained a percutaneous exposure",
"    <span class=\"nowrap\">",
"     (puncture/cut",
"    </span>",
"    injury), five had mucocutaneous exposures, two had both percutaneous and mucocutaneous exposures, and two had an unknown route of exposure. Forty-nine exposures were to blood from an HIV-infected source, one to visibly bloody fluid, four to an unspecified fluid, and three to concentrated virus in a laboratory.",
"   </p>",
"   <p>",
"    Exposed HCP were nurses (24), laboratory technicians (16), nonsurgical physicians (6), and others (11). Twenty-six of these HCP have developed the acquired immunodeficiency syndrome (AIDS). To date, there are no confirmed seroconversions in surgeons and no seroconversions after exposures from a suture needle.",
"   </p>",
"   <p>",
"    In addition, 143 cases of HIV infection or AIDS have occurred among HCP in the United States who have reported a history of occupational exposure and who have not reported other risk factors for HIV, but for whom seroconversion after exposure was not documented.",
"   </p>",
"   <p>",
"    As of 2002, 35 documented seroconversions following occupational exposure and 85 possible occupationally acquired HIV infections were reported in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/15\">",
"     15",
"    </a>",
"    ]. Cases of HIV seroconversion following occupational exposures are not systematically documented and reported in most other regions of the world.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28866693\">",
"    <span class=\"h1\">",
"     RISK OF TRANSMISSION OF OTHER BLOODBORNE PATHOGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of transmission of hepatitis B virus (HBV) to unvaccinated healthcare personnel or a vaccinated nonresponder is much higher than HIV. The risk of hepatitis C virus transmission from an infected source is about sixfold greater compared with HIV (1.8 versus 0.3 percent). Management of healthcare personnel exposed to these viruses, including postexposure prophylaxis for hepatitis B virus, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     POSTEXPOSURE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of healthcare personnel (HCP) immediately after a significant exposure to blood or body fluids from HIV-infected patients is critically important in reducing the likelihood of transmission and in insuring that the legal rights of the employee and the institution are upheld.",
"   </p>",
"   <p>",
"    All institutions should have a readily available policy for managing serious exposures. In the US, such a policy is required and must comply with regulations of the Occupational Safety and Health Administration (OSHA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\", section on 'OSHA requirements'",
"    </a>",
"    .) The policy should be distributed to all employees and should be readily available in the Employee Health Service and the Emergency Department.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial actions following exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial response to any exposure of HCP to blood should be immediate cleansing of the exposed site. For skin exposures, the area should be washed with soap and water. Small wounds and punctures may be cleansed with an antiseptic such as an alcohol-based hand hygiene agent, since alcohol is virucidal to HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV). Other antiseptics such as iodophors, chloroxylenol (PCMX) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    (CHG) also inactivate HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For mucosal surface exposure, the exposed mucus membranes should be flushed with copious amounts of water. Eyes should be irrigated with saline or water. There is no evidence that expressing fluid by squeezing the wound will further reduce the risk of bloodborne pathogen transmission. Guidelines for hand washing and infection control can be accessed through the",
"    <a class=\"external\" href=\"file://www.cdc.gov/handhygiene/Guidelines.html\">",
"     Centers for Disease Control and Prevention",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Documentation of the exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical information on the source patient for the exposure and the recipient HCP should be documented. This includes risk factors and serologic tests for HIV, and hepatitis B and C. The nature and time of the exposure should also be described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Definition of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this topic and when evaluating HCP at risk for occupational infection with HIV, &ldquo;exposure&rdquo; is defined as contact with potentially infectious blood, tissue, or body fluids in a manner that allows for possible transmission of HIV and therefore requires consideration of postexposure prophylaxis (PEP).",
"   </p>",
"   <p>",
"    Such potentially infectious contacts are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A percutaneous injury (eg, a needlestick or cut with a sharp object)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Contact of mucous membrane or nonintact skin (eg, exposed skin that is chapped, abraded, or afflicted with dermatitis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Body fluids of concern include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Body fluids implicated in the transmission of HIV: blood, semen, vaginal secretions, other body fluids contaminated with visible blood.",
"     </li>",
"     <li>",
"      Potentially infectious body fluids (undetermined risk for transmitting HIV): cerebrospinal, synovial, pleural, peritoneal, pericardial, and amniotic fluids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fluids that are",
"    <strong>",
"     not",
"    </strong>",
"    considered infectious unless they contain blood include feces, nasal secretions, saliva, gastric secretions, sputum, sweat, tears, urine, and vomitus.",
"   </p>",
"   <p>",
"    In addition, any direct contact (ie, without barrier protection) to concentrated HIV in a research laboratory or production facility is considered an \"exposure\" that requires clinical evaluation and consideration of PEP.",
"   </p>",
"   <p>",
"    Intact skin is an effective barrier against HIV infection, and contamination of intact skin with blood or other potentially contaminated fluids is not considered an exposure and does not require PEP.",
"   </p>",
"   <p>",
"    These definitions of exposure are consistent with those detailed by the United States Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28866545\">",
"    <span class=\"h3\">",
"     Determining HIV status of the source",
"    </span>",
"    &nbsp;&mdash;&nbsp;If unknown, the presence of HIV infection in the source patient should be determined with a rapid HIV test [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/19\">",
"     19",
"    </a>",
"    ]. If testing in the source patient is delayed, PEP should still be initiated while awaiting test results. If the source is found to be HIV-negative, PEP should be discontinued. (See",
"    <a class=\"local\" href=\"#H1087328\">",
"     'Indications for prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The CDC recommends routine HIV testing for persons 13 to 64 years of age, unless the patient \"opts out.\" The implication for healthcare personnel in the United States (US) is that it is now more likely that the source will have been tested. Some states in the US still require informed consent for HIV serologic testing, but many waive this requirement in the event of occupational exposure.",
"   </p>",
"   <p>",
"    Clinicians should also be aware of rare case reports where the source patient tested HIV-seronegative and was later found to have primary HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/20\">",
"     20",
"    </a>",
"    ]; these rare events do not alter guidelines for routine antibody testing but do highlight the importance of testing for HIV RNA if clinically indicated. It is important to be cautious in interpretation of low viral loads (&lt;5000",
"    <span class=\"nowrap\">",
"     c/mL)",
"    </span>",
"    since these are often lab errors and patients with acute retroviral syndrome usually have very high viral loads. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Counseling of healthcare personnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk assessment is particularly important for HCP to make educated decisions about PEP since the consequences are great and the stress is extraordinary. They should also be well informed of the benefits and risks of PEP and of the importance of close follow-up. Specifically, the following issues should be discussed with exposed HCP:",
"   </p>",
"   <p>",
"    HCP should be informed of the risk associated with the specific exposure experienced. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Risk of transmission of HIV'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With percutaneous or sharps injuries from an HIV-infected source, the risk of HIV infection averages",
"      <span class=\"nowrap\">",
"       3/1000,",
"      </span>",
"      but varies greatly depending on the inoculum size (source viral load and volume of blood), the depth of penetration, and exposure to a hollow bore versus suture needle.",
"     </li>",
"     <li>",
"      Exposure of source blood to intact skin is considered \"no risk\". There are no confirmed cases of HIV transmission in HCP with skin abrasions, cuts, sores, or other breaches in skin integrity, but a theoretical risk is estimated at",
"      <span class=\"nowrap\">",
"       1/1000.",
"      </span>",
"     </li>",
"     <li>",
"      All documented transmissions have involved source blood, bloody body fluids, or laboratory cultures of HIV. Bites have never been implicated in transmission to HCP, but have resulted in HIV transmission in other settings.",
"     </li>",
"     <li>",
"      The risk is likely considerably lower if the source has unknown HIV status or if prior tests were negative.",
"     </li>",
"     <li>",
"      The HCP may also be at risk for other bloodborne pathogens, such as hepatitis B or C.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy and disadvantages of PEP should be discussed. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Postexposure prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indirect evidence shows that postexposure prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      alone can reduce the risk of HIV infection. Current multidrug regimens are likely much more effective in preventing infection. However, even when properly provided, PEP does not assure complete prevention of HIV infection.",
"     </li>",
"     <li>",
"      The goal is to initiate PEP within one to two hours of exposure. It is thought that benefit of PEP is greatly diminished after 24 to 36 hours.",
"     </li>",
"     <li>",
"      Several options exist for PEP, and side effects are an important consideration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk reduction strategies should be employed to prevent transmission of HIV should the HCP acquire infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the event of HIV infection postexposure, the greatest risk of transmission to other individuals is in the first 6 to 12 weeks. Exposed HCP should be instructed on measures to reduce the potential risk of HIV transmission to others. This usually means condom use or abstinence from sex and refraining from blood, plasma, organ, tissue, and semen donation until the six-month serologic test is negative.",
"     </li>",
"     <li>",
"      There is no need to modify a healthcare provider&rsquo;s patient-care responsibilities after an exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follow-up is important to identify HIV infection or adverse effects of the PEP regimen, if administered. (See",
"    <a class=\"local\" href=\"#H218540\">",
"     'Testing for HIV'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H27\">",
"     'Patient monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood testing for HIV will be done at baseline, six weeks, three months, and six months following exposure. Exposed HCP should report any subsequent febrile or mononucleosis-like illness so that they can be evaluated for acute retroviral syndrome.",
"     </li>",
"     <li>",
"      For those who opt to take PEP, blood testing will also be done at two and four weeks to evaluate for drug toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific counseling is warranted for women of childbearing age. (See",
"    <a class=\"local\" href=\"#H218648\">",
"     'PEP during pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Female HCP who have childbearing potential need to be aware of the limited data on the safety of antiretroviral drugs, especially during the first trimester of pregnancy. However, data from the HIV pregnancy registry, with over 4000 in utero exposures to antiretroviral agents, suggest overall safety [",
"      <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For women who are breastfeeding, temporary discontinuation of breastfeeding following exposure until the six month serologic test is negative should be considered. This is to avoid infant exposure to both antiretroviral agents and, should the mother become infected, HIV in breastmilk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=see_link\">",
"       \"Prevention of HIV transmission during breastfeeding in resource-limited settings\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218540\">",
"    <span class=\"h2\">",
"     Testing for HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV serologic testing at baseline, six weeks, three months and six months following the exposure with or without prophylaxis is important to identify HIV seroconversion. The majority of individuals who seroconvert will do so within the first three months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnostic assays for HIV infection\", section on 'Standard HIV-1 antibody tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some advocate an additional test at 12 months since at least three HCP seroconverted at 6 to 12 months postexposure. One case report of delayed HIV seroconversion has been reported in a HCP who acquired HIV and HCV infections simultaneously through a needlestick exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/22\">",
"     22",
"    </a>",
"    ]. In light of this case report, extended HIV follow-up (eg, for 12 months) is recommended for any HCP who becomes infected with HCV after exposure to a source coinfected with HIV and HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/18\">",
"     18",
"    </a>",
"    ]. Whether extended follow-up is indicated in other situations (eg, exposure to source with",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    in absence of HCV seroconversion) is unclear. Extended follow-up may also be considered in exposed persons with a medical history suggestive of impaired humoral immunity.",
"   </p>",
"   <p>",
"    People potentially exposed to HIV should also be advised to seek medical attention if they develop symptoms consistent with primary HIV infection, often described as a \"mononucleosis-like syndrome\". The most common findings are fever, lymphadenopathy, sore throat, mucocutaneous lesions,",
"    <span class=\"nowrap\">",
"     myalgia/arthralgia,",
"    </span>",
"    diarrhea, headache,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    and weight loss. The usual time from HIV exposure to the development of symptoms is two to four weeks, although incubation periods as long as ten months have been seen. HIV viral load testing should be performed in these patients to diagnose acute retroviral syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=see_link&amp;anchor=H18410709#H18410709\">",
"     \"Acute and early HIV infection: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Otherwise, routine monitoring of HIV viral load in an attempt to detect early infection should generally not be performed because of the risk of false positive test results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POSTEXPOSURE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For healthcare personnel (HCP) with a percutaneous, mucous membrane, or nonintact skin exposure to body fluids of concern, as defined above, from a patient with known HIV infection, we offer postexposure prophylaxis (PEP). We typically use a three-drug regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    . Other equally acceptable alternatives include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    or ritonavir-boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from animal models have supported the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    in preventing transmission of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. In addition, the benefit of zidovudine in reducing maternal-infant transmission of HIV from 25.5 to 8.3 percent in a randomized controlled trial (the AIDS Clinical Trial Group Protocol 076) suggests that zidovudine could also have a beneficial role in postexposure prophylaxis (PEP) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link&amp;anchor=H328983#H328983\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\", section on 'Data on prevention of HIV perinatal transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best available clinical evidence for PEP comes from a case-control study that evaluated HCP with percutaneous exposures to HIV-infected blood in the United States and Europe between 1987 and 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/5\">",
"     5",
"    </a>",
"    ]. There were 33 cases (HCP who became infected with HIV) and 665 controls (HCP who did not become infected). Risk factors for seroconversion were deep injury, injury by device with visible blood contamination, injury with needle from source blood vessel, and terminal illness in the source. In a multivariate analysis controlling for these risk factors, cases were significantly less likely to have taken",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    after exposure than controls (OR 0.19, 95% CI 0.06-0.52). This study has several methodological limitations including retrospective design, heterogeneity of data source, and small number of events. Nevertheless, the cumulative data from this study in addition to the results from other prevention models (eg, studies of HIV perinatal transmission and PEP in primates) overall support the efficacy of PEP.",
"   </p>",
"   <p>",
"    The mechanism by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    prevents HIV transmission is incompletely understood. The benefit in reducing maternal-infant transmission cannot be entirely explained by a reduction in plasma levels of HIV RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/27\">",
"     27",
"    </a>",
"    ]. It is known that older PEP regimens that included zidovudine were not perfect, since there have been at least six reported cases of HCP who contracted HIV infection despite receiving a zidovudine-containing combination regimen within two hours of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/18\">",
"     18",
"    </a>",
"    ]. This drug is no longer generally recommended due to poor tolerance resulting in high rates of noncompliance.",
"   </p>",
"   <p>",
"    Subsequent data show that combination antiretroviral therapy is significantly better than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    in reducing perinatal transmission rates from 8 to &lt;2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/28\">",
"     28",
"    </a>",
"    ]. Improved efficacy is likely with combination antiretroviral therapy for PEP as well. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Selection of antiretroviral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1087328\">",
"    <span class=\"h2\">",
"     Indications for prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a HCP with a percutaneous, mucous membrane, or nonintact skin exposure to body fluids of concern from a patient with known HIV infection, we offer PEP. If the HIV status of the source patient is unknown, we offer PEP while awaiting HIV testing of the source only if that patient has risk factors for HIV infection (eg, injection drug use). If the source with unknown HIV status is felt to be low risk, the decision on whether to initiate PEP may be delayed while awaiting rapid HIV testing of the source as long as results can be available within two hours. If the source patient is unknown, we do not recommend PEP unless it occurred in a setting where exposure to HIV is likely (eg, a needlestick from a sharps container in an HIV clinic). &nbsp;",
"   </p>",
"   <p>",
"    In all cases, the decision to administer PEP must weigh the risk of infection with HIV against the toxicity and inconvenience of PEP. The individual preferences of the exposed HCP will generally determine the decision about whether to proceed with PEP.",
"   </p>",
"   <p>",
"    In general, exposures can be categorized into low or high risk depending on the nature of the exposure and the HIV disease in the source (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Risk of transmission of HIV'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-risk percutaneous exposure: Low-risk sharps injuries are those that occur through a solid needle, appear superficial, and occur from a low-risk source, such as a patient with an HIV viral load &lt;1500",
"      <span class=\"nowrap\">",
"       copies/mL.",
"      </span>",
"     </li>",
"     <li>",
"      High-risk percutaneous exposure: High-risk sharps injuries include those from a hollow bore needle, from a device with the presence of visible blood, or from a needle that was in an artery or vein of the source patient.",
"     </li>",
"     <li>",
"      Mucocutaneous exposures: These are considered low risk except large volumes of blood from a source who has a plasma HIV viral load &gt;1500",
"      <span class=\"nowrap\">",
"       copies/mL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;PEP should be initiated as quickly as possible. The goal is to start within one to two hours or earlier after exposure, often using a \"starter pack\" with appropriate drugs that are immediately available. A delay in the time to initiate PEP is hypothesized to reduce efficacy. This concept is supported in primate models of PEP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The median time to initiation of PEP among 435 HCP in the US was 1.8 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For occupational exposures with a low-risk source, it may be more reasonable to perform a rapid test for HIV on the source patient, provided the results will be available within two hours. PEP should be offered if the rapid test is positive, but the result should be considered provisional until confirmed by Western blot. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) recommendations are to offer prophylaxis up to 24 to 36 hours after exposure; for longer time lapses, the recommendation is to seek advice from an expert. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Sources for further information'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Selection of antiretroviral therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H986399\">",
"    <span class=\"h3\">",
"     Preferred antiretroviral regimens for PEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;We favor a three-drug regimen for all HCP who opt for PEP. Because the newer antiretroviral agents have not been studied with regards to efficacy for PEP specifically, regimens for PEP should include those agents that have proven to be most potent and best tolerated in patients with HIV. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    <span class=\"nowrap\">",
"     (TDF/FTC)",
"    </span>",
"    combined with a third drug:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , or ritonavir-boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef83600 \" href=\"UTD.htm?19/1/19484\">",
"     table 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    We suggest the following PEP regimen for HCP with an occupational exposure to HIV, provided the source does not have detectable virus with known resistance to these agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       Tenofovir-emtricitabine",
"      </a>",
"      <span class=\"nowrap\">",
"       (300/200",
"      </span>",
"      mg once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      (400 mg twice daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other preferred regimens are: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       Tenofovir-emtricitabine",
"      </a>",
"      <span class=\"nowrap\">",
"       (300/200",
"      </span>",
"      mg once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      (300 mg once daily) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (100 mg once daily)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       Tenofovir-emtricitabine",
"      </a>",
"      <span class=\"nowrap\">",
"       (300/200",
"      </span>",
"      mg once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      (800 mg once daily) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (100 mg once daily) with food",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    cannot be used (eg, renal dysfunction with creatinine clearance &lt;50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    (30 mg twice daily) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (150 mg twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    (200 mg once daily) in place of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    in the above regimens. Depending on the degree of renal dysfunction, the doses may need to be adjusted.",
"   </p>",
"   <p>",
"    These recommendations differ from the 2005 CDC guidelines for prevention of HIV infection following an occupational exposure, which recommend two nucleosides for low-risk exposures and two nucleosides plus a boosted protease inhibitor for high-risk exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/18\">",
"     18",
"    </a>",
"    ]. These guidelines can be found at the",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/PDF/rr/rr5409.pdf\">",
"     Centers for Disease Control and Prevention website",
"    </a>",
"    ; an update is expected in the near future. However, many authorities, including UpToDate authors and editors, no longer advocate the two-tiered CDC recommendations nor the agents recommended due to substantial progress in drug development and clinical experience since their publication.",
"   </p>",
"   <p>",
"    Although we do not recommend it, if a two-drug regimen is used, our first choice is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    <span class=\"nowrap\">",
"     (300/200",
"    </span>",
"    mg once daily) based on potency, convenience of once-daily dosing, and excellent tolerance.",
"   </p>",
"   <p>",
"    In the US, assistance with choosing a regimen can be obtained by calling the National Clinicians' Postexposure Prophylaxis Hotline (PEPline) at 888-448-4911.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H986415\">",
"    <span class=\"h3\">",
"     Rationale for preferred PEP regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    combined with any of these three agents are that none have been shown inferior for HIV therapy in a clinical trial, all have sustained long-term experience, and all are relatively well tolerated. Minor issues that may favor one or another are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       Raltegravir",
"      </a>",
"      is not affected by food, is well tolerated, and has rare drug interactions. Rare cases of a severe systemic-cutaneous reaction resembling Stevens-Johnson syndrome have been reported.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       Ritonavir",
"      </a>",
"      -boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      requires combination with ritonavir and administration with food.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       Ritonavir",
"      </a>",
"      -boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      requires combination with ritonavir and food. Concomitant use of gastric acid blockers decreases absorption. Another minor disadvantage is an increase in direct bilirubinemia, which is harmless and resolves with drug discontinuation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    can exacerbate renal failure in patients with pre-existing renal dysfunction. In cases of significant renal dysfunction,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"     zidovudine-lamivudine",
"    </a>",
"    <span class=\"nowrap\">",
"     (AZT/3TC)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    <span class=\"nowrap\">",
"     (d4T/3TC)",
"    </span>",
"    can be used with one of the third agents above. Stavudine (d4T) appears better tolerated than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    within the limited time course of PEP administration. Zidovudine often causes gastrointestinal toxicity immediately, whereas stavudine primarily leads to adverse events chronic administration. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    is included in one of the preferred regimens for initial treatment of HIV-infected patients based on potency and durability, but it has the major disadvantage of central nervous system toxicity in the first two to three weeks of administration. While this is acceptable for patients anticipating a lifetime of treatment, it may be ill-advised for HCP who take treatment for one month and usually work in positions that require high-level cognitive function. Choosing a well-tolerated regimen is critical since up to 75 percent of HCP taking PEP experience side effects and less than half complete the one-month course [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/18,30,31\">",
"     18,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of the new agents, there is interest in the C-C chemokine receptor type 5 (CCR5) inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , since new infection involves CCR5 tropic virus exclusively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/32\">",
"     32",
"    </a>",
"    ]. However, experience with this drug is too limited to be recommended at the current time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Drugs to avoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that should",
"    <strong>",
"     NOT",
"    </strong>",
"    be used for PEP are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    . These may cause severe and sometimes life-threatening side effects, especially during the first few weeks of exposure. Nevirapine should not be used for PEP because of the risk of liver toxicity and Stevens-Johnson syndrome. Abacavir should not be used due to the risk of severe hypersensitivity reactions, which occur in five to eight percent of patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     Indinavir",
"    </a>",
"    has the disadvantage of requiring significant water intake and is associated with risk of kidney stones. The risk-benefit of PEP does not justify the use of these drugs, especially when there are so many alternatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H986438\">",
"    <span class=\"h2\">",
"     Specific populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     PEP options for drug-resistant virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard PEP regimens may be inappropriate when the source is infected with a strain of HIV that is known or likely to be resistant to antiretroviral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/18\">",
"     18",
"    </a>",
"    ]. Although there are no studies examining this issue, it is appropriate to tailor a regimen by selecting antiretroviral medications to which the source HIV is believed to be sensitive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the source of an occupational HIV exposure is infected with resistant virus, expert consultation is advised [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/18\">",
"     18",
"    </a>",
"    ]. An HIV specialist can help design the appropriate regimen by considering the results of resistance testing for the source patient on the current ART regimen. If no resistance testing is available, an HIV specialist can often predict which mutations may be present if the source patient has virologic failure on the current regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/33\">",
"     33",
"    </a>",
"    ]. This is particularly helpful since results from resistance testing performed after exposure will not be available soon enough to affect the choice of PEP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some general principles can be applied to designing such a regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the source patient has a history of drug resistance, but has viral suppression on the current antiretroviral therapy, a PEP regimen using the same medications, or medications with similar patterns of susceptibility, is generally appropriate, if safe and well tolerated.",
"     </li>",
"     <li>",
"      If the source patient is taking antiretroviral therapy but still has detectable viremia, it makes clinical sense to choose other medications that are unlikely to show cross-resistance when picking a PEP regimen.",
"     </li>",
"     <li>",
"      Resistant strains that were documented in the past on a prior regimen are less relevant for drug selection for PEP since these probably make up only the minority species in the source patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of drugs to which a resistant virus likely has no cross-resistance was exemplified in the cases of two HCP who had significant blood exposure from the same HIV-infected patient who had a history of extensive drug resistance mutations in the reverse transcriptase and protease genes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/35\">",
"     35",
"    </a>",
"    ]. Both were treated for one month with combination therapy that included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    without evidence of seroconversion more than six months after initial exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218648\">",
"    <span class=\"h3\">",
"     PEP during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pregnant HCP who have an occupational exposure to HIV and choose to initiate postexposure prophylaxis (PEP), we typically use the same regimen as noted above, namely",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    (available as Truvada) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    . An alternative regimen is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"     zidovudine-lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"     lopinavir-ritonavir",
"    </a>",
"    . Prospective data from the Antiretroviral Pregnancy Registry has not demonstrated an increase in overall birth defects with first trimester antiretroviral drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/21\">",
"     21",
"    </a>",
"    ]. Drugs not recommended for use in pregnancy include d4T and ddI.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    is the only antiretroviral known to be teratogenic and should not be used for PEP in pregnant women. Risks to the mother and fetus must be balanced against the probability of transmission of HIV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the remote probability of HIV transmission in most cases, some experts would recommend obtaining a negative pregnancy test in female HCP with childbearing potential prior to the administration of PEP or require signed informed consent. However, pregnancy, per se, should not preclude PEP for exposed HCP, and pregnant HCP should be offered a regimen with the best chance of preventing infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/36\">",
"     36",
"    </a>",
"    ]. Ideally, an HIV expert in consultation with a high-risk obstetrician should provide PEP for pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because they may be offered PEP regimens that are more highly associated with side effects, pregnant HCP electing PEP should be followed scrupulously for adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218770\">",
"    <span class=\"h3\">",
"     PEP in resource-limited settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many resource-limited settings, the prevalence of HIV is higher than in resource-rich settings, but the availability of antiretroviral agents may be more limited. The World Health Organization also recommends PEP for HCP following an isolated exposure to infectious or potentially infectious body fluids from an HIV-infected source in such regions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/37\">",
"     37",
"    </a>",
"    ]. It recommends a dual nucleoside reverse transcriptase (NRTI) regimen for most PEP unless the source is known to have resistant virus or the background prevalence of resistance to antiretroviral therapy is greater than 15 percent. In these cases a boosted protease inhibitor is recommended as a third agent. When feasible, we favor a three-drug regimen for all HCP who opt to take PEP because of the reasons listed above and the fact that baseline community resistance is not always readily available. (See",
"    <a class=\"local\" href=\"#H986415\">",
"     'Rationale for preferred PEP regimens'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended duration of PEP is four weeks because a course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    for this duration appeared protective in some studies; however, the optimal duration of PEP is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/18,38\">",
"     18,38",
"    </a>",
"    ]. It is biologically plausible that shorter durations of PEP would be as effective, especially with more potent agents. However, until further data are available, we administer PEP for four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Patient monitoring",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects are reported by about half of patients who receive PEP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/29,39-42\">",
"     29,39-42",
"    </a>",
"    ]. Most side effects are mild, but about one-third of patients discontinue treatment because of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/29,39,43,44\">",
"     29,39,43,44",
"    </a>",
"    ]. The most common side effects are nausea and fatigue; headache, vomiting, and diarrhea are also common [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/29,39-42\">",
"     29,39-42",
"    </a>",
"    ]. Rare but serious side effects include nephrolithiasis (with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    ), hepatitis, hyperglycemia, fevers, rashes, and pancytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/29,39\">",
"     29,39",
"    </a>",
"    ]. PEP with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    has resulted in some severe adverse events, including at least one case of hepatotoxicity requiring liver transplantation and three confirmed or possible cases of Stevens-Johnson syndrome; this agent is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for PEP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/29,45-48\">",
"     29,45-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One program that provided four weeks of PEP to 401 people with exposures outside the healthcare setting (94 percent were sexual exposures) also found a high rate of side effects including nausea (52 percent), fatigue (44 percent), headache (24 percent), diarrhea (15 percent), and anorexia (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/49\">",
"     49",
"    </a>",
"    ]. Side effects are more common with triple-drug PEP regimens that include a protease inhibitor than with dual NRTI PEP regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of these reports have been with regimens that included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and older generation protease inhibitors. In general, side effects are less frequent with newer agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , and ritonavir-boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    . Results of a study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    and raltegravir for nonoccupational PEP suggested that side effects associated with that regimen were mild and occurred at a frequency comparable to those historically reported for tenofovir-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/51\">",
"     51",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Adverse effects of specific agents are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=see_link\">",
"     \"Pharmacology of nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/56/11144?source=see_link\">",
"     \"Pharmacology of integrase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Laboratory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who receive PEP should be monitored for drug toxicity. Testing should include a complete blood count including differential, and tests of hepatic and renal function at baseline and at two and four weeks after initiation of PEP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/47/7930/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients treated with a protease inhibitor should also be monitored for hyperglycemia. Additional testing may be indicated depending on the PEP regimen selected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serious abnormalities of laboratory values warrant a switch in the antiretroviral regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link&amp;anchor=H3#H3\">",
"     \"Modifying HIV antiretroviral therapy regimens\", section on 'Indications for changing antiretroviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SOURCES FOR FURTHER INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 24-hour hotline is available through The National Clinicians' Postexposure Prophylaxis Hotline, phone number 1-888-448-4911.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/31/18931?source=see_link\">",
"       \"Patient information: Blood or body fluid exposure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk to healthcare personnel (HCP) of contracting HIV from exposure to body fluids from an HIV-infected patient is very low. The average risk of seroconversion after a needlestick injury is about 3 per 1000 with no prophylaxis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk of transmission of HIV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first response to a percutaneous exposure should be to wash the area thoroughly with soap and water; for punctures and small lacerations, cleaning the area with an alcohol-based hand hygiene agent is reasonable. Exposed mucous membranes should be irrigated copiously with water or saline. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial actions following exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCP should report exposures promptly to obtain HIV screening for both the HCP and the source patient (according to institution guidelines), and to discuss the need for postexposure prophylaxis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Documentation of the exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the stress and emotional impact of an occupational exposure to HIV, explicit counseling on the actual risk of the exposure and the benefits and disadvantage of postexposure prophylaxis is important. Exposed HCP should also be instructed on reducing the risk of potential transmission of HIV and means of monitoring for seroconversion. HIV screening on the exposed individual should be performed at baseline, 6 and 12 weeks, and at six months after exposure. The majority of individuals who seroconvert will do so within the first three months. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Counseling of healthcare personnel'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H218540\">",
"       'Testing for HIV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For HCP with a percutaneous, mucous membrane, or nonintact skin exposure to potentially infectious body fluids from a patient with known HIV infection, we offer postexposure prophylaxis (PEP). In all cases, the decision to administer PEP must weigh the risk of infection with HIV against the toxicity and inconvenience of PEP. The individual preferences of the exposed HCP will generally determine the decision about whether to proceed with PEP. If the HIV status of the source patient is unknown, we typically administer PEP while awaiting HIV testing of the source only if that patient has risk factors for HIV infection. If the source with unknown HIV status is felt to be low risk, the decision on whether to initiate PEP may be delayed while awaiting rapid HIV testing of the source as long as results can be available within two hours. If the source patient is unknown, we do not give PEP unless it occurred in a setting where exposure to HIV is likely. (See",
"      <a class=\"local\" href=\"#H1087328\">",
"       'Indications for prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the decision is made to administer postexposure prophylaxis, it should be started as early as possible after an exposure (ideally within one to two hours, or sooner if possible). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For HCP who are offered and agree to take PEP, we suggest a three rather than a two-drug regimen, regardless of the severity of the exposure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      . Alternative regimens that are equally acceptable are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      -boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      or ritonavir-boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef83600 \" href=\"UTD.htm?19/1/19484\">",
"       table 1",
"      </a>",
"      ). Drugs that should",
"      <strong>",
"       NOT",
"      </strong>",
"      be used for PEP are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      , which may cause severe and sometimes life-threatening side effects, especially during the first few weeks of exposure. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Selection of antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of regimen, when the source is receiving a failing regimen, is best made in consultation with an HIV expert. For pregnant HCP who have an occupational exposure to HIV and choose to initiate postexposure prophylaxis, we typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"       zidovudine-lamivudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"       lopinavir-ritonavir",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       Efavirenz",
"      </a>",
"      should not be used in women who are or might be pregnant. In the US, assistance with choosing a regimen can be obtained by calling the National Clinicians' Postexposure Prophylaxis Hotline (PEPline) at 888-448-4911. (See",
"      <a class=\"local\" href=\"#H986438\">",
"       'Specific populations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is recommended that postexposure prophylaxis (PEP) be continued for four weeks, although the duration needed to achieve maximal benefit is not known. PEP should be discontinued if testing shows that the source patient is HIV-negative. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      People receiving postexposure prophylaxis should be monitored for adverse reactions to the drugs and for drug interactions. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Occupational Safety and Health Administration requirements in the United States and the management of exposure to hepatitis B and C viruses are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link\">",
"       \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"      </a>",
"      .).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/1\">",
"      Henderson DK, Fahey BJ, Willy M, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. Ann Intern Med 1990; 113:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/2\">",
"      Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. The CDC Cooperative Needlestick Surveillance Group. Ann Intern Med 1993; 118:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/3\">",
"      Baggaley RF, Boily MC, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 2006; 20:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/4\">",
"      Henderson DK. Management of needlestick injuries: a house officer who has a needlestick. JAMA 2012; 307:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/5\">",
"      Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/6\">",
"      Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/7\">",
"      Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/8\">",
"      Skurnick JH, Palumbo P, DeVico A, et al. Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J Infect Dis 2002; 185:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/9\">",
"      Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341:394.",
"     </a>",
"    </li>",
"    <li>",
"     International Healthcare Worker Safety Center, University of Virginia. U.S. EPINet Sharps Injury and Blood and Body Fluid Exposure Surveillance Research Group. Blood and Body Fluid Exposure Report for 2009; 32 hospitals contributing data, 329 total exposures. file://www.healthsystem.virginia.edu/pub/epinet/epinetdatareports.html#reports (Accessed on June 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/11\">",
"      Fisman DN, Harris AD, Rubin M, et al. Fatigue increases the risk of injury from sharp devices in medical trainees: results from a case-crossover study. Infect Control Hosp Epidemiol 2007; 28:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/12\">",
"      Makary MA, Al-Attar A, Holzmueller CG, et al. Needlestick injuries among surgeons in training. N Engl J Med 2007; 356:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/13\">",
"      Do AN, Ciesielski CA, Metler RP, et al. Occupationally acquired human immunodeficiency virus (HIV) infection: national case surveillance data during 20 years of the HIV epidemic in the United States. Infect Control Hosp Epidemiol 2003; 24:86.",
"     </a>",
"    </li>",
"    <li>",
"     Surveillance of Occupationally Acquired HIV/AIDS in Healthcare Personnel, as of December 2010 file://www.cdc.gov/HAI/organisms/hiv/Surveillance-Occupationally-Acquired-HIV-AIDS.html.",
"    </li>",
"    <li>",
"     file://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1194947320156.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/16\">",
"      Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee, HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/handhygiene/Guidelines.html (Accessed on May 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/18\">",
"      Panlilio AL, Cardo DM, Grohskopf LA, et al. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/19\">",
"      Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med 2009; 361:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/20\">",
"      Giulieri S, Schiffer V, Yerly S, et al. The trap: professional exposure to human immunodeficiency virus antibody negative blood with high viral load. Arch Intern Med 2007; 167:2524.",
"     </a>",
"    </li>",
"    <li>",
"     Committee, A.P.R.S., Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2011. 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/22\">",
"      Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med 1997; 336:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/23\">",
"      Shih CC, Kaneshima H, Rabin L, et al. Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis 1991; 163:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/24\">",
"      Van Rompay KK, Marthas ML, Ramos RA, et al. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3'-azido-3'-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother 1992; 36:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/25\">",
"      Martin LN, Murphey-Corb M, Soike KF, et al. Effects of initiation of 3'-azido,3'-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis 1993; 168:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/26\">",
"      Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/27\">",
"      Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/28\">",
"      Watts DH. Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 2002; 346:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/29\">",
"      Gerberding JL. Clinical practice. Occupational exposure to HIV in health care settings. N Engl J Med 2003; 348:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/30\">",
"      Beekmann SE, Fahrner R, Henderson DK, Gerberding JL. Zidovudine safety and tolerance among uninfected healthcare workers: a brief update. Am J Med 1997; 102:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/31\">",
"      Wang SA, Panlilio AL, Doi PA, et al. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry. Infect Control Hosp Epidemiol 2000; 21:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/32\">",
"      M&eacute;chai F, Quertainmont Y, Sahali S, et al. Post-exposure prophylaxis with a maraviroc-containing regimen after occupational exposure to a multi-resistant HIV-infected source person. J Med Virol 2008; 80:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/33\">",
"      Roland ME, Martin JN, Grant RM, et al. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. J Infect Dis 2001; 184:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/34\">",
"      Puro V. Genotypic resistance tests for the management of postexposure prophylaxis. Scand J Infect Dis Suppl 2003; 106:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/35\">",
"      Siegel MO, Kan VL, Benator DA. Raltegravir for postexposure prophylaxis following occupational exposure to HIV. AIDS 2008; 22:2552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/36\">",
"      Henderson DK. HIV postexposure prophylaxis in the 21st century. Emerg Infect Dis 2001; 7:254.",
"     </a>",
"    </li>",
"    <li>",
"     Joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection file://whqlibdoc.who.int/publications/2007/9789241596374_eng.pdf (Accessed on May 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/38\">",
"      Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. The HIV postexposure prophylaxis registry: Final report, 17 October 1996 through 31 March 1999. The Centers for Disease Control and Prevention, Glaxo Wellcome Inc, Merck and Co, Inc. March 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/40\">",
"      Parkin JM, Murphy M, Anderson J, et al. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet 2000; 355:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/41\">",
"      Lee LM, Henderson DK. Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. Drug Saf 2001; 24:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/42\">",
"      Garb JR. One-year study of occupational human immunodeficiency virus postexposure prophylaxis. J Occup Environ Med 2002; 44:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/43\">",
"      Rabaud C, Burty C, Grandidier M, et al. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. Clin Infect Dis 2005; 40:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/44\">",
"      Luque A, Hulse S, Wang D, et al. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Infect Control Hosp Epidemiol 2007; 28:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/45\">",
"      Centers for Disease Control and Prevention (CDC). Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001; 49:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/46\">",
"      Warren KJ, Boxwell DE, Kim NY, Drolet BA. Nevirapine-associated Stevens-Johnson syndrome. Lancet 1998; 351:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/47\">",
"      Benn PD, Mercey DE, Brink N, et al. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet 2001; 357:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/48\">",
"      Patel SM, Johnson S, Belknap SM, et al. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr 2004; 35:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/49\">",
"      Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis 2001; 183:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/50\">",
"      Garcia MT, Figueiredo RM, Moretti ML, et al. Postexposure prophylaxis after sexual assaults: a prospective cohort study. Sex Transm Dis 2005; 32:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/47/7930/abstract/51\">",
"      Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012; 59:354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3764 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7930=[""].join("\n");
var outline_f7_47_7930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK OF TRANSMISSION OF HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28866473\">",
"      Risk by exposure type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors for seroconversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk of exposure by profession",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28866504\">",
"      Documented seroconversions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28866693\">",
"      RISK OF TRANSMISSION OF OTHER BLOODBORNE PATHOGENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      POSTEXPOSURE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial actions following exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Documentation of the exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Definition of exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28866545\">",
"      - Determining HIV status of the source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Counseling of healthcare personnel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H218540\">",
"      Testing for HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POSTEXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1087328\">",
"      Indications for prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Selection of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H986399\">",
"      - Preferred antiretroviral regimens for PEP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H986415\">",
"      - Rationale for preferred PEP regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Drugs to avoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H986438\">",
"      Specific populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - PEP options for drug-resistant virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H218648\">",
"      - PEP during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H218770\">",
"      - PEP in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Patient monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Laboratory monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SOURCES FOR FURTHER INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3764\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3764|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/1/19484\" title=\"table 1\">",
"      ART for occupational PEP against HIV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=related_link\">",
"      Acute and early HIV infection: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=related_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=related_link\">",
"      Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=related_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26410?source=related_link\">",
"      Nonoccupational exposure to HIV in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/31/18931?source=related_link\">",
"      Patient information: Blood or body fluid exposure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/56/11144?source=related_link\">",
"      Pharmacology of integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=related_link\">",
"      Pharmacology of nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=related_link\">",
"      Prevention of HIV transmission during breastfeeding in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42456?source=related_link\">",
"      Surgical issues in HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_47_7931="Cutaneous features";
var content_f7_47_7931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F77125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F77125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cutaneous features of urticarial vasculitis versus common urticaria",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Urticarial vasculitis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common urticaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Description",
"       </td>",
"       <td>",
"        Painful, tender, burning, and/or pruritic",
"       </td>",
"       <td>",
"        Mainly pruritic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistence",
"       </td>",
"       <td>",
"        Between 24 and 72 hours",
"       </td>",
"       <td>",
"        Between 8 to 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Residual effects",
"       </td>",
"       <td>",
"        Purpura or hyperpigmentation",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Predilection",
"       </td>",
"       <td>",
"        Anywhere",
"       </td>",
"       <td>",
"        Anywhere",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7931=[""].join("\n");
var outline_f7_47_7931=null;
var title_f7_47_7932="Risk factors for gallstones";
var content_f7_47_7932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major risk factors for the development of gallstones",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female sex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Genetic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pima Indians and certain other Native Americans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chileans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Rapid weight loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Very low calorie diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Surgical therapy of morbid obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemolytic anemias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertriglyceridemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Estrogen and oral contraceptives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Clofibrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ceftriaxone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Octreotide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Terminal ileal resection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Gallbladder stasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Total parenteral nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Postvagotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Octreotide or somatostatinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Spinal cord injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduced physical activity (at least in men)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7932=[""].join("\n");
var outline_f7_47_7932=null;
var title_f7_47_7933="Short-term effects of MI on blood lipids";
var content_f7_47_7933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Short-term effects of MI on blood lipids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 209px; height: 251px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sequential changes in LDL and HDL cholesterol and total triglycerides (TG) following an acute myocardial infarction. The reductions in LDL and HDL cholesterol and rise in triglycerides begin within a few days and do not resolve for up to 30 days.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Rosenson RS. J Am Coll Cardiol 1993; 22:933.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7933=[""].join("\n");
var outline_f7_47_7933=null;
var title_f7_47_7934="AC regimen for breast cancer";
var content_f7_47_7934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Doxorubicin and cyclophosphamide (AC) chemotherapy for breast cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        <p>",
"         Cycle length: 21 days.",
"        </p>",
"        Total cycles: 4 cycles (in the adjuvant setting).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doxorubicin",
"        </strong>",
"       </td>",
"       <td>",
"        60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with normal saline (NS) to a final concentration of 2 mg/mL and administered as an IV bolus over three to five minutes into a free flowing IV infusion of NS or 5 percent dextrose in water (D5W). If needed, doxorubicin can be further diluted after reconstitution in NS or D5W and given as a slow IV infusion administered over 15 to 60 minutes",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cyclophosphamide",
"        </strong>",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 to 500 mL NS or D5W and administer over 30 to 60 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        Patients receiving cyclophosphamide should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days thereafter) and void frequently to reduce the risk of hemorrhagic cystitis",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Doxorubicin is a vesicant and can cause significant tissue damage if an extravasation occurs. For peripheral infusions, the IV line should be recently placed into a large, intact vein, with good blood return established immediately prior to starting the infusion. The IV or catheter site should be continuously monitored throughout drug administration infusion. If extravasation occurs, apply ice to the site and consider use of dexrazoxane. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Not applicable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Dose adjustment is not necessary for doxorubicin in renal impairment. The need for cyclophosphamide dose reduction in renal insufficiency is controversial. For patients with preexisting hepatic impairment, dose adjustments in doxorubicin and cyclophosphamide may be needed. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiac issues:",
"        </strong>",
"        A baseline assessment of LVEF is recommended, with periodic reassessment of during therapy. The risk of doxorubicin-associated cardiac dysfunction is related to cumulative dose. The risk is increased in patients with underlying heart disease, when anthracyclines are used concurrently with other cardiotoxic agents or radiation, and in patients previously treated with mediastinal or chest wall irradiation. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin",
"        <sup>",
"         [2]",
"        </sup>",
"        . Further information on anthracycline-associated cardiotoxicity, including discussion about prevention and treatment, is available. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count every two weeks prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Serum electrolytes and liver and renal function tests every two weeks prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Cumulative doxorubicin dose should be monitored. As appropriate, assess cardiac function prior to initiation of AC then periodically during treatment. For patients receiving AC for metastatic disease, consider the addition of dexrazoxane after 300 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        total dose. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Subsequent cycles should be delayed until the absolute neutrophil count is greater than 1000/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count greater than 100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . If there is more than a three week delay in treatment, a dose reduction of 25 percent is recommended",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for hepatic or renal dysfunction:",
"        </strong>",
"        Guidelines for managing doxorubicin and cyclophosphamide in patients who have changes in kidney or liver function during therapy are addressed in detail separately. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiotoxicity:",
"        </strong>",
"        Guidelines for managing doxorubicin in patients with symptomatic cardiac dysfunction or asymptomatic changes in LVEF during therapy are addressed in detail separately. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Fisher B, et al. J Clin Oncol 1990; 8:1483.",
"      </li>",
"      <li>",
"       Adriamycin (doxorubicin hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011).",
"      </li>",
"      <li>",
"       Cytoxan (cyclophosphamide) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 19, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7934=[""].join("\n");
var outline_f7_47_7934=null;
var title_f7_47_7935="Gram stain wound 1 with answer";
var content_f7_47_7935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Staphylococcus aureus in wound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of purulent drainage from a wound (x1000) shows many inflammatory cells and Gram positive cocci in singles, pairs, and clusters. Staphylococcus aureus grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_47_7935=[""].join("\n");
var outline_f7_47_7935=null;
